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Abbreviations 
 
Å Ångström 
A280 UV absorbance at wavelength of 280 nm 
Amp Ampicillin 
Community-acquired pneumonia CAP 
DLS Dynamic light scattering 
DMSO Dimethyl sulfoxide 
DPPC Dipalmitoylphosphatidylcholine 
DTT Dithiothreitol 
DVDC Drop vapor diffusion crystallization 
E. coli Escherichia coli 
ERSF European Synchrotron Radiation Facility 
ESI-MS Electrospray Ionisation 
HABA Hydroxy-azophenyl-benzoic acid 
HZI Helmholtz-Zentrum für Infektionsforschung 
IPTG Isopropyl-β-D-thiogalactopyranoside 
L. pneumophila Legionella pneumophila 
LPC Lysophosphatidylcholine 
LPLA Lysophospholipase  A 
MALDI-TOF Matrix Assisted Laser Desorption Ionisation 
– Time Of Flight 
MR Molecular replacement 
MS Mass spectrometry 
MWCO Molecular weight cutoff 
OD600 Optical density at wavelength of 600 nm 
OG Octyl-β-D-glucopyranoside 
PC Phosphatidylcholine 
PCR Polymerase chain reaction 
PEG Polyethylene glycol 
PG Phosphatidylglycerol 
PKCα Protein kinase Cα 
PLA Phospholipase A 
RH Hydrodynamic radius 
RKI Robert Koch Institute 
Rpm Rotations per minute 
R.T. Room temperature 
SD200 Superdex 200 (gel filtration column) 
SDS Sodium dodecyl sulfate 
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SDS-PAGE SDS polyacrylamide gel electrophoresis 
SEC Size-exclusion chromatography 
SBDD Structure-based drug design 
SeMet Selenium methionine 
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Zusammenfassung 
 
Legionella pneumophila (L. pneumophila) ist die Hauptursache für 
Legionellose, deren ernste Form, die Legionärskrankheit, tödlich verlaufen 
kann. In letzter Zeit wurde in Deutschland ein starker Anstieg der Legionellose 
als Ursache für ambulant erworbene Pneumonie sowohl in stationär als auch in 
ambulant behandelten Krankenhauspatienten beobachtet. Die Bakterien 
besitzen eine Vielzahl von Phospholipasen, welche Phospholipide spalten und 
dadurch verschiedenen Produkte freisetzen, die die bakterielle Invasion und 
Virulenz unterstützen. Zu ihnen gehört PlaB, die vorherrschende zell-
assoziierte Phospholipase deren Aktivität zu Lungenentzündung und 
markantem Velust von funktionaler epithelialer Zellschicht und somit Zersörung 
von Lungengewebe führt. Der detailierte Mechanismus der PlaB-Aktivität ist 
noch unbekannt. Es ist darüber hinaus ein neuartiges Protein für welches noch 
keine homologe Struktur zur Verfügung steht. Strukturelle Information über 
PlaB könnte deshalb die Grundlage bilden für die Aufklärung des 
enzymatischen Mechanismus im Allgemeinen und der PlaB-Familie im 
Besonderen. Die Sruktur des Komplexes aus dem Protein und seinen 
Substraten würde auch die Möglichkeit zur Entdeckung neuer Medikamente 
bieten, welche antibakterielle Resistenzen umgehen könnten.    
 
In der vorliegenden Arbeit wurden Wege zur großmaßstäblichen Expression 
und Reinigung von PlaB und seinen SeMet-markierten Derivaten etabliert, und 
das Protein wurde bis zur Homogenität gereinigt. Kristalle wurden gezüchtet, 
und ein nativer Datensatz mit einer Auflösung von 2.6 Å wurde gesammelt. Alle 
Kristalle waren jedoch entweder verzwillingt, wie im Falle der hexagonalen 
Kristallform, oder oder sehr stark anisotrop, wie im Falle der triklinen 
Kristallform. Das machte es unmöglich, das Phasenproblem zu lösen und die 
Struktur zu bestimmen. Externe Parameter und chemische Modifikationen des 
Proteins wurden untersucht, um diese Probleme zu lösen. Kristalle mit anderer 
Morphologie konnten von einer C-terminal verkürzten Version des Proteins 
gezüchtet werden, was Anlass zur Hoffnung gibt, dass diesen nicht die 
gleichen Probleme anhaften, die zum Haupthindernis dieser Arbeit wurden.   
 
 
SUMMARY                                                                                                          6 
 
Summary 
 
Legionella pneumophila (L. pneumophila) is the major cause of Legionellosis, 
of which the severe form, Legionnaires’ disease, can lead to death. Recently, it 
is increasingly observed as a leading cause of community-acquired pneumonia 
(CAP) in hospitalized and ambulatory patients in Germany. The bacteria 
possess a variety of phospholipases that cleave phospholipids, releasing 
various products which facilitate the invasion and virulence of bacteria. Among 
them, PlaB is the major cell-associated phospholipase, the activity of which 
leads to lung inflammation and prominent loss of functional epithelial cell layer 
in the lung and hence to the destruction of lung tissue. The detailed mechanism 
of the PlaB activity remains unknown. It is also a novel protein for which no 
structural homolog is available. Structural information of PlaB may thus 
establish a foundation to elucidate enzymatic mechanism of the enzyme in 
particular and PlaB family in general. Structure of a complex between the 
protein and its substrates will also offer lead for the discovery of novel drug to 
counteract antibacterial resistance. 
 
In this work, schemes for large-scale expression and purification of PlaB and 
SeMet-labeled derivatives were established, and the protein was purified to 
homogeneity. Crystals were grown and a native data set of the protein crystal 
was obtained at the resolution of 2.6 Å. However, the crystals were either 
twinned when it was in hexagonal form or seriously anisotropic in triclinic form. 
This made it impossible to obtain phase information for structural 
determination. External parameters as well as chemical modifications of the 
protein itself were investigated intensively to solve these issues. A different 
crystal morphology of a C-terminal truncated version of the protein was 
obtained, giving hope that it would not have these two issues that have been 
the bottleneck of this work.  
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1 Introduction 
 
1.1 L. pneumophila and pneumonia diseases 
 
Gram-negative L. pneumophila was first discovered by McDade et al. (1977) 
after an outbreak of Legionnaires’ disease, a severe fibrinopurulent pneumonia. 
The outbreak occurred among veterans at a hotel during an American Legion 
convention in Philadelphia in 1976, resulting in 29 deaths and the 
hospitalization of 147 people (Fraser et al. 1997). The pathogen was named in 
memory of the deceased veterans. The air-conditioning system was later 
identified as the source of the infection during the convention (Kwaik et al. 
1998). The oldest confirmed outbreak, however, was reported to occur in 1957 
at Minnesota meat packing plant (Osterholm et al. 1983). 
 
L. pneumophila belongs to the genus Legionella, which consists of over 50 
species identified to date. Twenty-four of these species have been found to be 
associated with human disease, but L. pneumophila is responsible for 
approximately 90% of Legionnaires’ disease cases (Hilbi et al. 2010; Diederen 
2008; Fields et al. 2002; Muder et al. 1986; Yu et al. 2002; Marston et al. 1997). 
L. pneumophila serogroup 1 is responsible for 84% of cases worldwide caused 
by L. pneumophila, among at least 15 serogroups (Yu et al. 2002). Previous 
studies provided evidences that L. pneumophila is more pathogenic to human 
than other Legionella species (Newton et al. 2010). 
 
The latest record in 2010 indicated a significant increase in the incidence of L. 
pneumophila diseases in general and Legionnaires’ disease in particular. In 
Germany, the bacterium is a leading cause of CAP in hospitalized and 
ambulatory patients (Carratalà & Garcia-Vidal 2010). The mortality of severe L. 
pneumophila is high (30%) and poor outcomes are correlated with pre-existing 
comorbidities (e.g. cardiac disease, diabetes, acute renal failure). Smoking, 
chronic obstructive lung disease, diabetes, chronic corticosteroid therapy, and 
weakened immune systems are known risk factors for Legionnaires’ disease 
(Nicolini et al. 2013; Hilbi et al. 2010). 
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1.2 State of treatment and drug resistance 
 
Treatment therapy for patients hospitalized with community-acquired 
pneumonia is established empirically (Fields et al. 2002). Previous study 
showed that there has been an association between delay in starting 
appropriate therapy and increased mortality (Heath et al. 1996). L. 
pneumophila has been shown to be 1,000-fold more resistant to inactivating 
effects of antibiotics (rifampicin, ciprofloxacin) when being protected inside 
macrophage and amoeba (Barker et al. 1995). In order to achieve killing of L. 
pneumophila antibiotics must be capable of penetrating into macrophage cells 
(Barker et al. 1995). The current antibiotics of choice for treatment of 
Legionnaires’ disease are azithromycin, erythromycin and fluoroquinolones, 
although rifampicin is often also recommended (Fields et al. 2002). 
Aminoglycosides (such as gentamicin, kanamycin and streptomycin), 
chloramphenicol and cefoxitin are also active against L. pneumophila at low 
concentrations (Thornsberry et al. 1978; Edelstein & Meyer 1980).  
 
These antibiotics target cytoplasmic components of the bacteria. Azithromycin 
and erythromycin bind to the 50S subunit of the bacterial ribosome and inhibits 
translation of mRNA (Zuckerman 2004). Fluoroquinolones inhibit DNA 
replication by targeting DNA gyrase or topoisomerase IV in the enzyme-DNA 
complex (Hooper 2001). Aminoglycosides inhibit protein synthesis (Kotra et al. 
2000). Rifampicin binds to DNA-dependent RNA polymerase and inhibits 
bacterial DNA-dependent RNA synthesis (Hartmann et al. 1985).  
 
However, the emergence of drug-resistance of L. pneumophila has been 
reported (Moffie & Mouton 1988; Fong et al. 2010; Ferhat et al. 2009), urging 
the need for discovery of novel drug classes. 
 
 
1.3 Pathogenic pathway of Legionella bacteria 
 
Legionella bacteria are ubiquitous in freshwater environments (Fliermans et al. 
1981). L. pneumophila has been detected in a wide range of fresh water 
sources, from natural aquatic to human-made water systems (Fields et al. 
2002). However, Legionella bacteria are not free-living aquatic bacteria. During 
their life cycle, they parasitize or form a commensal relationship with amoebae 
(Figure 1.1) (Rowbotham 1980; Fields 1996; Kwaik et al. 1998; Newton et al. 
2010). 
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Figure 1.1: Life cycle of L. pneumophila within protozoa. (1) L. pneumophila infects 
protozoa. (2) Upon infection, L. pneumophila locates in a membrane-bound vacuole and is 
surrounded with host cell organelles, such as mitochondria and rough ER. L. pneumophila-
containing vacuole does not fuse with lysosomes. (3) 3a. L. pneumophila replicates in large 
numbers. 3b. Some mutants fuse to lysosomes and undergo lysosomal degradation. (4) 
Different forms of the infectious particle: excreted legionella-filled vesicles, intact legionella-
filled amoebae, or free legionella that have lysed their host cell. (5) Transmission to human via 
inhalation of aerosols containing infectious particles. (6) Leaving the host cells, free legionella 
reinfect other protozoa, or recolonize biofilms. Reprinted from (ASM News. 66(10) (2000): 609-
616) (Newton et al. 2010). 
 
 
Legionella infection usually occurs through inhalation of contaminated aerosols 
produced by human-made water systems and faucets (Albert-Weissenberger et 
al. 2007). Cooling waters are the frequent sources in reported community-
acquired outbreaks (Minh et al. 2006). Potable water may also be an important 
source of sporadic and epidemic legionellosis (Fraser 1985). Other modes of 
transmission of Legionella are aspiration and direct instillation into the lung (RR 
et al. 1986). However, person-to-person transmission has never been reported 
(Newton et al. 2010). 
 
The interaction of L. pneumophila with eukaryotic cells is similar to its 
interaction with environmental hosts. After inhalation of contaminated aerosol 
droplets, the bacteria reach the alveolar parts of the lungs where they are 
phagocytosed by alveolar macrophages. Uptake of L. pneumophila by 
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monocytes and macrophages has been shown to occur through coiling 
phagocytosis (Horwitz 1984) or conventional phagocytosis (Molmeret et al. 
2004). The microbes can block the fusion of lysosomes with the phagosome, 
preventing the acidification of its phagosome (Horwitz & Maxfield 1984; Horwitz 
et al. 1983) and therefore escape the phagosome-lysosome degradation 
pathway. Once inside the macrophages or monocytes, the L. pneumophila 
phagosome is surrounded by host cell organelles such as mitochondria and 
vesicles (Horwitz et al. 1983). The bacterium begins to replicate until the 
nutrients of the host macrophage are consumed. The newly born bacteria move 
into their transmission phase, lyse the host macrophage (Molmeret et al. 2010) 
and restart the infection cycle. The process of lysing the host cells leads to the 
destruction of lung cells (Figure 1.2), resulting in Legionnaires’ disease (Winn & 
Myerowitz 1981).  
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Figure 1.2: Tissue destruction caused by L. pneumophila within the human lung over 
time, visualized by Hematoxylin-eosin stain. A: A human lung tissue explant (HTLE) infected 
by L. pneumophila after 48 h. It was observed that collagen fibers within the alveolar septa 
appeared loose (arrow), indicating decreasing septal integrity. B, C, and D: Uninfected control 
HTLEs after 2, 24, and 48 h of incubation, respectively. E, F, and G: HTLEs infected by L. 
pneumophila at 2, 24, and 48 h after infection, respectively. Integrity lost of connective tissue, 
delamination of alveolar epithelial cells and protein exudate in the alveolar lumen (*) are 
phenomena observed in infected tissue, in comparison with uninfected controls. After 48 h of 
incubation, L. pneumophila-infected tissue exhibits severe damage (G). H: Using anti-Mip 
antibody to visualize L. pneumophila, severe tissue damage at the sites where the bacteria 
located (Jäger et al. 2014). 
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Various virulence factors and machineries of L. pneumophila participating in 
cytopathology of Legionnaires’ disease have been described, including protein 
secretion systems as well as cytotoxic or hemolytic factors. Protein secretion 
systems are in charge of delivering virulence proteins of the bacteria passing 
through bacterial inner and outer membranes to their specific place of action 
(De Buck et al. 2007). For example, the Icm/Dot system involves in the 
promotion of phagocytosis, creating a nutrient-rich organelle that escapes the 
lysosomal degradation pathway, preserving the integrity of the L. pneumophila 
phagosome, the induction of apoptosis and lysis of the host cells (Molmeret et 
al. 2007). Several virulent proteins involved in pathogenesis of L. pneumophila 
have been identified including proteases, pore-forming toxins and bacterial 
lipolytic enzymes. Among these factors, bacterial phospholipases play 
important roles in the bacterial pathogenesis. Their enzyme activities result in 
destruction of the host cell membrane, or in products that manipulate host cell 
functions in a way that benefits the bacteria. Details on their functions and role 
in bacterial pathogenesis will be discussed in the next section.    
 
 
1.4 Functions and role of the bacterial phospholipases 
in virulence 
 
Phospholipases hydrolyze ester bonds of phospholipids (PL) into fatty acids 
and other lipophilic substances. There are 4 groups, termed phospholipases A-
D, attacking different positions of the phospholipid (Figure 1.3). Phospholipase 
A (PLA) hydrolyses the carboxylester bonds at the sn-1 or sn-2 position, 
releasing fatty acids together with a lysophospholipid. This lysophospholipid 
can be further cleaved by a lysophospholipase A (LPLA), resulting in 
glycerophospholipid (Figure 1.4). Phospholipase B (PLB) acts on both fatty acid 
residues. Phospholipase C (PLC) and phospholipase D (PLD) attack the 
glycerol oriented and the alcohol-oriented phosphodiester bond, respectively. 
By cleaving components of lipid bilayers and releasing bioactive molecules, the 
bacterial phospholipases are involved in many disease-promoting processes 
from membrane destruction to interference with host cell signaling pathways 
(Figure 1.3) (Schmiel & Miller 1999; Istivan & Coloe 2006; Lang & Flieger 2011; 
Kuhle & Flieger 2013).  
 
In recent years, an increasing number of virulence factors with PLA activity 
involved in events ranging from invasion into host cells to severe lung disease 
have been discovered (Banerji et al. 2008). PLA activity has been shown to 
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play the major role in lung surfactant destruction and hemolysis by L. 
pneumophila (Flieger, Gong, et al. 2000; Flieger, Gongab, et al. 2000). Up to 
date, 15 potential and confirmed PLA or LPLA enzymes have been identified. 
These proteins are either secreted into the culture medium or associated with 
the bacterium (Lang & Flieger 2011).   
 
 
 
 
Figure 1.3: Possible impacts of phospholipases on host cells. For example, PLA2 
cleavages of phostidylcholine results in lysophosphatidylcholine which possesses a variety of 
functions within eukaryotic cells that eventually leads to pore formation and cell lysis. 
Archidonic acid or 1,2-diacylglycerol derived from a phospholipid as a result of PLA2 or PLC 
activity, respectively, can act as second messengers involving in cellular signalling events. PLD 
activity results in lysophosphatidic acid that acts as as a lipid mediator. In particular, it plays as 
an inducer of cell proliferation, migration and survival. It also activates various signal 
transduction pathways, including those initiated by Ras- and Rho- GTPases, by binding to G-
coupled receptors with high affinity (Lang & Flieger 2011). 
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Figure 1.4: Two-step hydrolysis by L. pneumophila phospholipase A (PLA) and 
lysophospholipase A (LPLA). In the first hydrolysis step, L. pneumophila exhibits PLA activity 
which cleaves one fatty acid residue from a phospholipid (phosphatidylcholine) resulting in the 
cytotoxic agent lysophospholipid (lysophosphatidylcholine). In the second hydrolysis step, 
LPLA cleaves the second fatty acid chain from lysophospholipid and releases 
glycerophospholipid (glycerophosphatidylcholine) (modified from Banerji et al. 2008).  
 
 
1.5 PlaB – an important virulence factor of L. 
pneumophila 
 
Among phospholipases A and lysophospholipases A of L. pneumophila, PlaB is 
the first enzyme confirmed to be pathogenic, involved in replication in lung cells 
and dissemination of the bacteria in an in vivo guinea pig model (Schunder et al. 
2010). In this model, the guinea pigs were infected with either wild-type or a 
plaB mutant L. pneumophila strain. Two days after infection, the number of 
bacteria growing in lung and spleen was counted. It was observed that while 
the wild-type bacteria increased 400-fold in the lung, the plaB mutant bacteria 
increased only 20 fold. The dissemination of the plaB mutant bacteria to the 
spleen was 100 fold less than the wild type. Histopathology data of guinea pig 
lung tissue showed much more prominent inflammation, infection and tissue 
destruction in lungs infected by the wild type strain than in ones infected by the 
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plaB mutant strain. The endothelium of the lungs infected with the plaB mutant 
was nearly intact while accumulated endothelial debris blocking the alveoli was 
observed in lungs infected with the wild-type bacteria (Schunder et al. 2010).  
 
PlaB has both phospholipase and lysophospholipase activities and additional 
hemolytic potential. The enzyme mainly hydrolyses long-chain fatty acid 
substrates (PC and PG) with preferences for lipids containing fatty acyl 
residues larger than eight carbon atoms, as well as the resulting 
lysophospholipids (Flieger et al. 2004; Bender et al. 2009). DPPC, a main 
component of eukaryotic membrane and lung, is the preferred substrate of L. 
pneumophila PlaB (Flieger et al. 2004). This perfectly fits with the observation 
that Legionella occupy lung cells and lead to cell membrane destruction. 
Interestingly, the specificity for PC hydrolysis is vital for PlaB hemolytic activity. 
Mutations that resulted in loss of ~90% efficiency of PC cleavage also led to 
loss of hemolysis (Bender et al. 2009).  
 
PlaB is the most prominent cell-associated phospholipase A of L. pneumophila 
and its active part is presented to the external environment. These conclusions 
were drawn from the following facts: the supernatant of L. pneumophila 
exhibited no PlaB-related PLA activity and a plaB mutant almost completely lost 
its cell-associated lipolytic activity; the hemolytic activity of PlaB was shown to 
be contact-dependent (Flieger et al. 2004); sucrose density gradient 
centrifugation revealed PlaB was located in the outer membrane fractions, and 
its active part is susceptible for proteinase K digestion, suggesting its active 
part is exposed on the surface of the bacteria (Schunder et al. 2010).   
 
 
1.6 PlaB represents a novel lipase family 
 
Functionally speaking, it is obvious that PlaB is a member of lipase families. 
With around one hundred three-dimensional lipase structures representing 
around 30 organisms, current knowledge on lipase structures indicates that the 
enzymes share a common α/β hydrolase fold and a conserved catalytic triad 
serine (S), aspartic acid (D) and histidine (H). The α/β hydrolase fold generally 
consists of eight β strands connected by six α helices (Figure 1.5). The catalytic 
triad mostly arranged within conserved amino acid blocks. For example, 
catalytic serine is embedded in the typical GXSXG in true lipases (Arpigny & 
Jaeger 1999) or in GDSL motif in lipase family II (Godoy et al. 2012). See table 
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1.1 for more details on conserved motifs in which each catalytic residue is 
embedded.   
 
Figure 1.5: An example of the alpha/beta-hydrolase fold. Crystal Structure of a 
Thermostable Lipase from Bacillus stearothermophilus P1 (PDB id: 1ex9), α-helices are 
represented by red spirals, β-strands are indicated by arrows. Red dotted line represents for 
bacterial outer membrane (Tyndall et al. 2002). 
 
 
Table 1.1: Conserved motif around catalytic triad residues of lipase families 
Lipase 
family/Subfamily 
Consensus motif 
of catalytic S 
Consensus motif of 
catalytic D 
Consensus motif 
of catalytic H 
I GXSXG N(X)DGL(X)V N(X)HL(X)D 
II (GDSL) GDSL LFXDX XHPT 
III N/A N/A N/A 
IV (HSL) GDSAGG XDPL XHGF 
V GXSMGG GDXDX DXGHX 
VI GFSQG HGXXDXV MGHE 
VII N/A N/A N/A 
VIII N/A N/A N/A 
PlaB THSTG GSDGVV SHS 
 
Red: catalytic residue. N/A: consensus motif is not available (Adapted from alignment results of 
(Arpigny & Jaeger 1999)) 
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In structural view, however, PlaB and its homologs do not belong to any known 
lipase families. Although the enzyme also possesses the “classical” catalytic 
triad of nucleophilic serine 85, aspartate 203 and histidine 251, protein blast 
suggested it does not exhibit significant sequence identity to known lipases 
(Flieger et al. 2004). Moreover, the protein presents some unique features 
(Bender et al. 2009). The first glycine of the consensus motif GXSXG in true 
lipases is replaced with a threonine residue in PlaB (Figure 1.4, Table 1.1). 
Replacing this residue with glycine reduces activity of PlaB by 95%, while a 
substitution with valine reduced the DPPC/MPLPC hydrolysis activity up to 50% 
(Bender et al. 2009). These results indicated that this residue is crucial for the 
enzyme activity. The two other crucial catalytic residues are embedded in 
unique motifs that were not found in other characterised lipase families (Bender 
et al. 2009). Following the catalytic histidine of PlaB is the polar amino acid 
serine rather than non-polar, hydrophobic residues that are usually present in 
other lipases (Flieger et al. 2004) (Figure 1.4, Table 1.1). It is suggested from 
previous studies that this serine residue may play a vital role in the expression 
of phospholipase A activity. Replacing serine in the immediate vicinity of 
catalytic histidine by valine in Staphylococcus hyicus reduced phospholipase 
activity more than 10-fold (van Kampen et al. 1998), while replacing the leucine 
adjacent to the active-site histidine with serine converted the lipase of Bacillus 
thermocatenulatus into a phospholipase A (Kauffmann & Schmidt-Dannert 
2001). How exactly these differences in PlaB define its phospholipase activities 
remains unknown. 
 
 
 
Figure 1.6: Structural scheme of PlaB. The three brown arrows indicate positions of catalytic 
residues (in bold) and the unique motifs in which they are embedded, respectively (Adapted 
from (Kuhle in RKI, personal communication).   
 
 
Adjacent to the catalytic active domain of PlaB is a C-terminal extension of 
about 200 amino acids. The function of this domain is still unknown. Truncation 
of only 15 amino acids at the C-terminus is sufficient to stop the cell-associated 
phospholipase A activity, suggesting that the C terminus might be important for 
activation of PlaB (Flieger et al. 2004).  
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1.7 Structure-based drug design (SBDD) 
 
Detail information on the active site and other important regions of an enzyme 
at atomic level enables a chemist to design small molecules that bind to one of 
these sites and interfere with the enzyme’s activity (Beddell et al. 1976; Walsh 
1983; McPherson 1999). These small molecules are modeled by computer 
modeling programs and quite often, they are analogs of natural substrates of 
the enzyme. Experimental determination of the enzyme structure is perhaps the 
most accurate way of obtaining the necessary information for inhibitor design, 
which includes the rigidity, geometry of the binding site and its hydrophobic 
character, electrostatic landmarks, the chemical features, and mechanisms 
related to biological functions of the enzyme (McPherson 1999; Halgren 2009; 
Villoutreix et al. 2007; Cheng et al. 2007).  
 
Since the first published work describing SBDD for human hemoglobin in 1976 
(Beddell et al. 1976), SBDD has become a key step in the discovery of many 
new and important marketed drugs. For example, structural determination of 
the HIV protease allowed the successful design of five protease inhibitors that 
are now commercially available (Erickson et al. 1990; Roberts et al. 1990; Istry 
et al. 1994).  
 
In the field of antibacterial-drug discovery, various antibacterial drugs were 
developed and have had significant contributions for human society (Table I.2). 
However, the widespread global occurrence of bacteria resistant to the 
antibiotics and synthetic drugs has been emerging (Chopra 2013; Simmons et 
al. 2010; Agarwal & Fishwick 2010). Much effort has been spent to develop 
new drugs but they do not adequately meet growing medical needs (Chopra 
2013; Agarwal & Fishwick 2010). Developing derivatives from older classes has 
a disadvantage that they are prone to existing bacterial resistance 
mechanisms. Thus, new drug classes targeting new virulence factors are 
urgently needed, and SBDD offers a promising approach that allows to 
discover new drugs rationally.  
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Table 1.2: Targets and classes of antibacterial drugs (Simmons et al. 2010) 
Drug target Drug classes 
Cell wall synthesis Β-Lactams, bacitracin, cycloserine, fosfomycin and 
glycopeptides 
Cell membrane integrity Daptomycin and polymyxins 
Nucleotide biosynthesis Sulfonamides and trimethoprim 
DNA replication Quinolines, nitrofurans and nitromidazoles 
RNA synthesis Rifamycins 
Protein synthesis Aminoglycosides, chloramphenicol, fusidic acid, 
ketolides, macrolides, oxazolidinones, 
streptogramins, tetracyclines and mupirocin 
 
 
1.8 PlaB is a promising drug target 
 
Regarding drug delivery and targeting, PlaB represents a promising drug target 
because the enzyme is located outside the membrane and is hence more 
accessible as a drug target than other cytoplasmic proteins. Additionally, PlaB 
is crucial for bacteria growth in lung and dissemination of the bacteria to the 
spleens. Blocking PlaB can at least inhibit the dissemination of PlaB to other 
cells inside the host. It is hypothesized that PlaB may play some role in 
bacterial replication, too. If a drug can be designed in a way so it can penetrate 
macrophage, the inhibitor can then block the PlaB and therefore inhibit the 
bacterial replication inside lung cells. Furthermore, because PlaB is a novel 
lipase, the risk that the drug targets a human homolog is significantly reduced. 
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2 Aims of the study 
 
Despite extensively biochemical studies in Antje Flieger’s group at Robert Koch 
Institute (Wernigerode) where the enzyme was first identified and characterised, 
there remain many questions regarding the enzyme functions. For examples: 
 
1. How does structure of PlaB look like? 
2. How is PlaB activated and regulated? 
3. Is there any relevance between the unique amino acid environment 
around the catalytic triad of PlaB with its function and its ability of 
exhibiting both PLA and LPLA activity?  
4. Is metal required for enzyme activities? 
5. What is the function of the C-terminal domain?  
6. Why does PlaB favor long-chain phospholipids? 
7. Can the structure of PlaB be used as a template to design a PlaB 
inhibitor? 
 
The aim of this thesis was thus the crystallization and X-ray structure 
determination of PlaB in order to address the above-mentioned questions. 
 
A structure of PlaB will give us a detailed picture of the overall PlaB 
architecture, and will provide structural insights into its enzymatic activity. A 
structure of the enzyme in complex with its substrates will give invaluable 
information to chemists in finding new inhibitors. With atomic details of the 
substrate bound to the protein in the catalytic pocket, chemists may predict and 
synthesize homologs of substrates that can block the activity of the protein. 
Thus, the structures of both apo and substrate-bound form of PlaB can give us 
more knowledge about the function of C-terminal part of the protein.
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3 Materials and Methods 
 
3.1 Materials 
 
The chemicals were purchased with the quality standard “pro analysis” (p.a.) 
from the following companies: Eurofins MWG Operon, Fermentas, Fluka, GE-
Healthcare, Hampton Research, Invitrogen, Merck, Millipore, Qiagen, Roche, 
Roth, Sigma-Aldrich and Stratagene.  
 
 
3.1.1 Enzymes, standards 
 
Table 3.1: Enzymes and standards used in this work 
Enzyme Company 
DNase I Roche 
 
Standard  
Smart Ladder (DNA) 
Precision Plus Protein All Blue Standards 
(Protein) 
Eurogentec 
BIO-RAD 
 
 
3.1.2 Kits 
 
Table 3.2: Commercial kits used in this work 
Kit Company 
QIAprep® Spin Miniprep Kit Qiagen 
QuikChange® Site-Directed Mutagenesis Kit Stratagene 
Proteolysis screen Hampton Research 
 
 
3.1.3 Commercial crystallization screens 
 
The following crystallization screens from Qiagen were used for screening 
initial crystallization conditions: 
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Table 3.3: Commercial crystallization screens used for finding initial crystallization 
conditions 
The AmSO4 
The Anions 
The Cations 
The Cryo 
The Mb Class 
The MPD 
The PEGs I 
The PEGs II 
JCSG+ 
JCSG Core I 
JCSG Core II 
JCSG Core III 
JCSG Core IV 
The Classics 
The pH Clear 
 
 
The Morpheus screen from Molecular Dimensions, as well as the Additive 
Screen and Silver bullets from Hampton Research were also used. 
 
 
3.1.4 Plasmids 
 
Table 3.4: Plasmids used in this work 
Plasmid Derivation Reference 
pGP172-PlaB PlaB in pGP172 Kuhle et al. 2014 
pGP172-PlaB D203N Site directed mutagenesis of 
PlaB in pGP172 
Kuhle et al. 2014 
pGP172-PlaB 
D203N_459 
Truncation of the last 15 aa of 
PlaB D203N mutant in 
pGP172 
Kuhle et al. 2014 
 
 
Figure 3.1: Map of pGP172-PlaB plasmid. The plasmid carries a T7 promoter which is 
activated by IPTG, and an ampicillin resitance gene for selection (Kuhle et al. 2014). 
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3.1.5 Bacterial strains 
 
Table 3.5: Bacterial strains used in this work 
E.coli strains Genotype Source 
Top10 F  ,  mcr  A Δ(mrr -hsd RMS-mcr BC) Φ 80 
lac Z Δ M15 Δlac X74 
recA1 araD139 Δ(ara-leu)7697 gal  U gal  K 
rpsL endA1 nupG  
Invitrogen 
XL1-Blue 
supercompetent 
cells 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F´proAB lacIqZΔM15 Tn10 (Tetr)] 
Stratagene 
Tuner (DE3) F   lacY ompT gal dcm lon hsdSB(rB  mB 
) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 
nin5]) 
Novagen 
The first two strains were used for DNA preparation while the last strain was used for protein 
expression.  
 
 
3.1.6 Culture media and supplements  
 
Table 3.6: Compositions of culture media and supplements 
Type of medium Composition (in 1 L media) 
Luria Bertani (LB) 10 g tryptone, 5 g NaCl, 5 g yeast extract 
Terrific Broth (TB) 12 g tryptone, 24 g yeast extract 
SOC-Medium 20 g tryptone, 5 g yeast extract, 0.5 g NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 20 mM glucose 
Minimal medium* 20.8 mM NH4Cl, 24.5 mM KH2PO4, 24.9 mM 
Na2HPO4 
SeMet-nutrients* 1.11 M D-Glucose, 24.7 mM MgSO4, 332 µM 
Thiamine HCl, 260 µM Fe2(SO4)3 
Amino acid mix 100 mg Lysine, 50 mg Isoleucine, 50 mg Leucine, 50 
mg Valine 
*Although the final concentration of each composition is calculated for 1 L media, the minimal 
medium was prepared with volume of 900 ml, and SeMet nutrients were prepared in 100 ml. All 
of the media were autoclaved before using. SeMet nutrients and amino acid mix were prepared 
fresh.  
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3.1.7 Buffers and reagents 
 
Table 3.7: Buffer compositions 
Type of buffer Composition 
DNA loading buffer (10x) 10 mM Tris-HCl, pH 7.5, 0.05% (w/v) 
bromphenol blue, 1 mM EDTA, 50% 
glycerol 
TAE buffer 40 mM Tris-HCl pH 8.2, 20 mM 
CH3COONa, 1 mM EDTA 
Lysis and wash buffer 100 mM Tris pH 8.0, 100 mM NaCl, 
1mM EDTA, 5 mM DTT 
Elution buffer 100 mM Tris pH 8.0, 100 mM NaCl, 1 
mM EDTA, 5 mM DTT, 8 mM d-
Desthiobiotin 
Regeneration buffer 100 mM Tris-HCl pH 8.0, 150 mM NaCl, 
1 mM EDTA, 1 mM HABA 
SEC buffer 20mM Tris-HCl pH 8, 100mM NaCl, 
5mM DTT 
Ion exchange buffer A 20 mM HEPES pH 7.0, 100 mM NaCl, 
5 mM DTT 
Ion exchange buffer B 20 mM HEPES pH 7.0, 1 M NaCl, 5 
mM DTT 
SDS-PAGE lower buffer (4x) 1.5 M Tris-HCl, pH 8.8 
SDS-PAGE upper buffer (4x) 0.5 M Tris-HCl pH 6.8, 0.4% (w/v) SDS 
SDS-PAGE running buffer 25 mM Tris-HCl, 192 mM glycine, 0.1% 
(w/v) SDS 
SDS-PAGE sample buffer (2x) 1 ml 1 M Tris-HCl pH 6.8, 2.4 mM 
glycerol, 0.8 g SDS, 2 mg Coomassie 
blue G-250, 0.31 g DTT, add H2O to 10 
ml 
SDS-PAGE separating gel 4.7 ml H2O, 10 ml Polyacrylamide 
solution (33.3%), 5 ml 4x Lower buffer, 
0.2 ml SDS (10%), 20 µl TEMED, 50 µl 
APS (25%) 
SDS-PAGE stacking gel 5.9 ml milliQ water, 1.5 ml 
Polyacrylamide solution (33.3%), 2.5 ml 
4x Upper buffer, 15 µl TEMED, 25 µl 
APS (25%) 
Acidic native stacking gel (pH 6.8) 3% Acrylamide + Bis-Acrylamide, 62.5 
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mM KOH – CH3COOH, milli-Q water, 
0.05% APS, 5 µl TEMED (for 5 ml gel) 
Acidic native seperating gel (pH 4.5) 12% Acrylamide + Bis-Acrylamide, 375 
mM KOH - CH3COOH, milli-Q water, 
0.05% APS, 5 µl TEMED (for 5 ml gel) 
Neutral native stacking gel (pH 8.0) 3% Acrylamide + Bis-Acrylamide, 62.5 
mM KOH-MOPS, milli-Q water, 0.05% 
APS, 10 µl TEMED (for 5 ml gel) 
Neutral native seperating gel (pH 
6.8) 
12% Acrylamide + Bis-Acrylamide, 375 
mM KOH-MOPS, milli-Q water, 0.05% 
APS, 10 µl TEMED (for 5 ml gel) 
 
1x electrode buffer for acidic native 
gel 
350 mM β-alanine, 140 mM CH3COOH, 
milli-Q water  
1x electrode buffer for neutral native 
gel 
100 mM Histidine, 22 mM MOPS, milii-
Q water 
1x sample buffer for acidic native gel 30% Glycerol, 188 mM KOH- 
CH3COOH, milli-Q water, 0.1% 
Bromophenol blue 
1x sample buffer for neutral native 
gel 
30% Glycerol, 188 mM KOH-MOPS, 
milli-Q water, 0.1% Bromophenol blue 
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3.2 Methods 
 
3.2.1 Standard methods 
 
Methods used in this study are adapted from collections of methods and 
protocols (Sambrook, J. & Russell, D.W., 2001). Only variations of standard 
protocols are described below.  
 
 
3.2.2 Protein production and purification 
 
3.2.2.1 Expression of native protein 
 
The following procedure is for 1 L of cell culture. Typically 50 µg DNA plasmid 
was transformed into competent Tuner (DE3) cells. Single colonies were 
selected on an Ampicillin-containing LB-plate. One fresh colony was then used 
for inoculation of an overnight culture in 50 ml LB containing 100 µg/ml Amp at 
37°C, with shaking at 160 rpm. 10 ml overnight culture was used to inoculate 1 
L TB media containing antibiotics. The culture was grown at 37°C at 140 rpm 
until OD600 reached 0.6. Protein expression was induced with the addition of 
0.5 mM IPTG and the culture was incubated overnight at 20°C. Cells were 
harvested by centrifugation at 6,000 rpm at 4°C for 15 minutes and immediately 
lysed for protein purification. 
 
 
3.2.2.2 Expression of SeMet-labeled protein 
 
For the production of Se-Met labeled protein, the final protocol is as following: A 
fresh colony was used for inoculation of an overnight culture in 30 ml LB 
containing antibiotics at 37°C. 10 ml overnight culture was used to inoculate 1 L 
LB media containing antibiotics. When the OD600 reached 3.3, the culture was 
divided into 4 parts. The cells of each part were harvested by centrifugation at 
6,000 rpm for 15 minutes, the supernatant was removed, and the cell pellet 
was washed in 200 ml milli-Q water. The cells were then re-suspended in 
minimal medium supplemented with media nutrients, using a volume to yield an 
OD600 of 0.6. Amino acid mix, 60 µg/ml SeMet and 0.5 mM IPTG were added 
subsequently. The cells were incubated overnight at 20°C and afterwards 
harvested by centrifugation.    
 
 
MATERIALS AND METHODS 27 
 
3.2.2.3 Protein purification 
 
After resuspension in 30 ml lysis buffer containing DNase I, 20 mg lysozyme 
and 1 tablet of Complete Protease Inhibitor Cocktail, the cells were lysed by 
passing them two times through a homogenizer at 20 kpsi at 4°C. The lysate 
was cleared by centrifugation at 16,000 rpm for 45 min at 4°C. The supernatant 
was loaded onto a Strep-Tactin column pre-equilibrated with Wash buffer. 
Unspecifically bound protein was removed by washing the column with 5 
column volumes of Wash buffer. The target protein was eluted with 6 x 0.5 CV 
Elution buffer. The protein content of the eluted fractions was measured at 280 
nm and the purity was determined by 12% SDS-PAGE. Fractions with high 
enough protein content and purity were applied to reverse anion exchange. 
Fractions from the flow-through were collected, analyzed by SDS-PAGE and 
the fractions containing the pure protein were pooled and concentrated to 5 
mg/ml. Vivaspin concentrators with a molecular weight cutoff (MWCO) of 10 
kDa were used for concentration step.        
 
 
3.2.3 Protein analytical methods 
 
3.2.3.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was used to monitor the purity and yield during the protein 
purification (Laemmli 1970). The gels were composed of two parts: the upper 
stacking gel (5% acrylamide) and the lower resolving gel (12% acrylamide). 15 
µl of protein solution together with 5 µl of SDS loading buffer (containing DTT) 
were heated for 5 min at 95°C and then run at constant 40 mA per gel on an 
SDS gel until the dye front reached the end of the gel (usually 40 min). After the 
electrophoresis, the gel was washed with water to remove SDS and then 
stained with Instant Blue Coomassie dye for 10 min. 
 
 
3.2.3.2 Mass spectrometry (MS) 
 
The identity and the correct labeling of the produced proteins were confirmed 
by MS using either MALDI-TOF or ESI-MS. These analyses were carried out by 
Dr. Manfred Nimtz and Undine Felgenträger (HZI, Braunschweig). 
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3.2.3.3 Dynamic light scattering 
 
All purified protein samples were analyzed by DLS to assess their 
polydispersity (Proteau et al. 2010; Borgstahl 2007). The method was also 
used to examine the change of the oligomerization state of the protein at 
different concentrations. To remove large particles disturbing measurements, 
the protein solutions were centrifuge at 14,000 rpm for 20 min and 15 µl sample 
volumes were transferred in a dust-free DLS-cuvette. The experiments were 
carried out at 4°C and room temperature on a DynaPro Titan Temperature 
Controlled MicroSampler instrument (Wyatt Technologies). For each sample, 
25 individual experiments were recorded.  
 
 
3.2.3.4 Limited proteolysis screen 
 
Proti-Ace Kit (Hampton Research) was used to determine stable sub-domains 
suitable for crystallization. The kit consists of these below proteases:  
 
1. alpha Chymotrypsin (α-C): a serine endopeptidase that selectively 
cleaves peptide bonds formed by aromatic residues (tyrosine, 
phenylalanine and tryptophan). 
2. Actinase E (A-E): a serine protease displaying a wide range of substrate 
speficities. However, it prefers to hydrolyze peptide bonds on the 
carboxyl side of glutamic or aspartic acid. 
3. Bromelain (BR): a cysteine endopetidase that breaks peptide bonds of 
non-terminal amino acids. 
4. Clostripain (CL): a protease that cleaves proteins on the carboxyl 
peptide bond of arginine. 
5. Endoproteinase Glu-C (EG-C): a serine protease which hydrolyzes 
peptide bonds at the carboxyl side of glutamyl and aspartyl residues. 
The specificity of EG-C is dependent upon the buffer and pH employed 
as well as the structure around the potential cleavage site. No cleavage 
will occur if a proline residue is on carboxyl side. The enzyme also 
exhibits esterase activity. 
6. Elastase (EL) cleaves peptide chains mainly at the carboxy side of small, 
hydrophobic amino acids such as glycine, alanine and valine. 
7. Papain (PA) exhibits broad specificity, cleaving peptide bonds of basic 
amino acid, leucine, or glycine. It also hydrolyzes esters and amides, 
exhibits a preference for an amino acid bearing a large hydrophobic side 
chain at the P2 position. It does not accept Val at the P1' position. 
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8. Pepsin (PE) is most efficient in cleaving peptide bonds between 
hydrophobic and preferably aromatic amino acids such as phenylalanine, 
tryptophan and tyrosine. 
9. Proteinase K (P-K) is a serine protease. The predominant site of 
cleavage is the peptide bond adjacent to the carboxyl group of aliphatic 
and aromatic amino acids with blocked alpha amino groups. 
10. Subtilisin (SU) is not specific in activity. 
11.  Thermolysin (TH) specifically catalyzes the hydrolysis of peptide bonds 
containing hydrophobic amino acids. 
12.  Trypsin (TR) cleaves peptide chains mainly at the carboxyl side of the 
amino acids lysine or arginine, except when either is followed by proline. 
 
After 4 hours and after overnight incubation, aliquots were taken and 
proteolysis was stopped by mixing with SDS-PAGE sample buffer and heating 
for 60 sec at 95°C. The products of the reactions were analyzed by SDS-PAGE. 
 
 
3.2.3.5 Lysine methylation 
 
The methylation reaction was performed overnight in 50 mM HEPES (pH 7.5), 
250 mM NaCl at protein concentration of 1 mg/ml. Twenty micro liters freshly 
prepared 1 M dimethylamine-borane complex (ABC) and 40 µl 1 M 
formaldehyde were added per ml protein solution, and the reactions were 
gently mixed and incubated at 4°C for 2 hr. A further 20 µl ABC and 40 µl 
formaldehyde were added and the incubation continued for 2 h. Following a 
final addition of 10 µl ABC, the reaction was incubated overnight at 4°C. 
Precipitated protein was removed by centrifugation before purification of the 
soluble methylated protein by size-exclusion chromatography in 50 mM Tris-
HCl (pH 7.5), 200 mM NaCl. Appropriate peak fractions were pooled and 
concentrated, exchanged to 20 mM HEPES buffer (pH7.0), 100 mM NaCl in 
centrifugal concentrators to 5 mg/ml.  
 
 
3.2.4 Protein crystallization 
 
Concentrated and purified proteins were centrifuged at 14,000 rpm at 4°C for 
20 min before crystallization. All proteins were crystallised by hanging- and 
sitting-drop vapor diffusion methods at constant temperatures (4°C, 12°C, 20°C 
and 30°C). 
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3.2.4.1 Initial screening 
 
To screen for initial crystallization conditions, 0.2 µl of the concentrated, pure 
protein (typically 5 mg/ml) was mixed with the same volume of reservoir buffer 
of commercially available screens in a 96-well sitting drop vapor diffusion plate 
using the Honeybee 961 crystallization robot (Zinsser Analytics). The plate was 
sealed using a MancoTM Crystal Clear tape (Jena Bioscience). After one day 
and then every two days the plates were checked for the appearance of 
crystals with a microscope. 
 
 
3.2.4.2 Optimization – external parameters 
 
Initial crystals were evaluated and then further optimized in 24-well hanging 
drop vapor diffusion plates. External parameters that were used for optimization 
were protein and precipitant concentrations, pH, types of PEG, drop sizes and 
incubation temperatures. Crystal growth promoting additives were also tested 
using the Additive Screen and the Silver bullet screen (Hampton Research). 
 
 
3.2.4.3 Optimization – chemical modifications 
 
Chemical modifications were employed after exhausting above-mentioned 
approaches. Modification approaches included lysine methylation, limited 
proteolysis screening and C-terminal truncations to produce chemical modified 
proteins for initial crystallization screening. 
 
 
3.2.4.4 Cryo-protection 
 
During data collection, high-energy X-rays induce the formation of radicals 
within the crystal, resulting in crystal damage and thus rapid loss of diffraction 
(Garman 2010). This issue can be overcome by freezing the crystals in liquid 
nitrogen and collecting data in a stream of gaseous nitrogen held at 100°K. Yet, 
protein crystal and the surrounding mother liquor have high water content, 
freezing the crystal results in ice formation, which can damage the crystal 
and/or reduce the quality of the measured data by its own diffraction (ice rings). 
This is avoided by the addition of or co-crystallization with cryo-protectants. 
Several cryoprotectants were tested in this work, including glycerol, PEG 400, 
PEG 200, and paraffin. Glycerol was the best cryoprotectant. A solution of 
reservoir buffer including 20% glycerol was prepared, the crystal transferred 
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from its drop into this solution and then quickly frozen in liquid nitrogen.  
 
 
3.2.5 Heavy atom screen by native gel 
 
Native gels were prepared manually. The heavy atom at stock concentration of 
100 mM was diluted to 10 mM, then 2 µl of heavy atom was taken and mixed 
with 2 µl of protein and incubate at room temperature for 1 h. After that, the 
mixture was applied to native gel for 4 h at 70 V.  
 
 
3.2.6 X-ray analysis 
 
3.2.6.1 X-ray measurement 
 
X-ray crystallography is a fundamental technique to determine protein 
structures at atomic resolution. Structural details at atomic level allow 
elucidation of enzymatic mechanisms, molecular interactions and design of 
protein inhibitors. To determine protein structure by X-ray crystallography, a 
single crystal with sufficient size is required. The setup and mechanism of the 
X-ray diffraction analysis in this work are as follows: The crystal were frozen 
and irradiated with monochromatic X-rays, generated either by a rotating anode 
X-ray generator (home source) or a synchrotron. The crystals were kept at 
100°K all time during the measurement by a continuous stream of cold nitrogen 
gas. Upon interaction with the protein crystal, X-rays are diffracted and the 
diffraction is measured on a CCD device. The crystal is rotated around one axis 
in small step (0.5°) and one image is recorded for each step. These images are 
used to calculate the intensity and position of the reflections, which are input 
parameters for the determination of crystal structure.   
 
In which direction and under which angle an X-ray is diffracted is determined by 
Bragg`s Law (Figure 3-1). Knowing λ and θ, d is then computable. From d, 
lattice parameters can be calculated. 
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Figure 3.2: Diffraction of X-rays from two parallel planes following Bragg’s Law. n is an 
integral number, λ is the wavelength of the X-ray beam, d is the distance between two crystal 
planes and θ is the angle between incoming beam and crystal plane, usually also the crystal 
surface.  
 
 
3.2.6.2 Structural analysis 
 
The intensities and phase information of reflections are input parameters for the 
determination of crystals structure. Intensity of each diffraction spot should be 
strong enough for thoroughly analysis. However phase information is lost 
during measurements of protein crystals. Thus, methods to indirectly determine 
protein structures have been developed, including molecular replacement (MR) 
(Evans & McCoy 2007; Dodson 2007, Rossmann 2001; Rossmann & Blow 
1962), single/multiple wavelength anomalous dispersion (Hendrickson & Ogata 
1997), single/multiple isomorphous replacement (Green et al. 1954, Perutz 
1956; Blow & Rossmann 1961), or in some cases combination of these 
methods are utilized.  
 
 
3.2.6.3 Twin crystal analysis 
 
In this work, twinning crystals were detected by L test (Yeates 1997) which 
considers pairs of locally related reflections instead of twin related reflections. 
The statistic L can be evaluated without prior knowledge of the twin law (Rupp 
2009). 
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3.2.7 Surface site mutagenesis 
 
The plasmid was used as the template for the PCR to generate double or triple 
mutants following the standard QuikChange protocol for site-directed 
mutagenesis (Strategene) with some modifications as below: 
  
For mutant strand synthesis reaction, the sample mixture consisted of: 1x Pfu 
Ultra II buffer, 200 µM dNTP mix, 100 ng DNA templage, 0.5 µM forward primer, 
0.5 µM reverse primer and 2.5 U Pfu Ultra II DNA polymerase. 
 
 
Table 3.8: Cycling parameters for the site-directed mutagenesis method 
Segment Cycles Temperature Time 
1 1 95℃ 3 minutes 
2 15 95℃  52℃  68℃ 
1 minutes 
1 minutes 
12.4 minutes 
3 1 68℃ 1 hour 
   
 
After the amplification, 10 U DpnI was added into the mixture. The reaction 
mixture was then incubated immediately at 37℃ for 1 h to digest supercoiled 
dsDNA. The DpnI-treated DNA was transformed to XL1-blue competent cells. 
On the next day, 8 single clones were inoculated and subjected to DNA 
plasmid purification and sequencing to verify the correct mutations. 
 
  
3.2.8 Bio-informatic tools 
 
The Protparam tool (Gasteiger et al. 2003) was used to obtain theoretical data 
about the protein constructs such as extinction coefficients. Swiss-Model 
(Arnold et al. 2006), FUGUE (Shi et al. 2001), NCBI protein blast and Phyre 
(Kelley & Sternberg 2009) were used to search for structural homologs of PlaB. 
Sequence and secondary structure alignments were generated by NPS@ 
(Deléage et al. 1997). 
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4 Results 
 
4.1 Development of PlaB purification scheme 
 
4.1.1 Initial PlaB purification protocol 
 
An initial purification procedure for 1-2 L bacterial cell culture expressing PlaB 
protein was established by Katja Kuhle as part of her Ph.D thesis. Following 
this protocol, the plasmid was transformed into BL21 cells and the protein was 
produced after induction with 2 mM IPTG overnight at 20°C. After cell lysis, the 
protein was purified from the supernatant via Strep-tag affinity chromatography 
and the purity was analysed by SDS-PAGE. The protein was almost over 90% 
pure but some impurities still remained (Figure 4.1A). The major band at 53 
kDa was excised from the gel and confirmed as PlaB by mass spectrometry. 
Other bands were identified as E.coli proteins. 
 
 
4.1.2 Conventional chromatographies  
 
As impurities still remained visible on SDS-PAGE after affinity purification, 
cation exchange chromatography was applied followed by SEC to obtain a 
homogeneous population of the protein (Figure 4.1B and 4.1C). A single well-
resolved peak was observed at an estimated molecular weight of 200 kDa and 
SDS-PAGE of fractions underneath the peak confirmed that the peak 
corresponded to Strep-tagged PlaB. SEC thus confirms that the purified protein 
is pure and monodisperse.  
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Figure 4.1: Analysis of purified PlaB. A: SDS-PAGE analysis Strep-tag affinity purification of 
PlaB at R.T. M: Protein marker; lane 1: flow through, lane 2-3: wash 1 and wash 2, respectively, 
lane 4-9: elution fractions. B: SDS-PAGE analysis of protein fractions eluted from gel filtration 
following cation exchange. M: protein marker; lane 1 – 6: gel filtration fractions. The protein 
amount loaded on SDS-PAGE was the same with the amount using for the SDS-PAGE 
analysis after affinity purification. Only PlaB band was observed and impurities were not 
detected. C: Gel filtration profile of PlaB at 12°C, showing single and relatively symmetrical 
peak. Gel filtration buffer: 100 mM HEPES pH 7.0, 100 mM NaCl; Flow rate: 0.3 ml/min; 
Sample volume: 0.5 ml. 
 
 
However, after each step of chromatography a significant protein amount was 
lost. Eventually, 90% of protein amount was lost through steps of cation 
exchange, gel filtration and concentration. The obtained amount of protein, 
therefore, was only sufficient for initial crystallization screening but not for 
further crystallization optimization of the same batch. In order to obtain 
sufficient protein amount for crystallization optimization, the protein production 
was scaled up to 6-8 L of cell culture. At high yield, the protein was quickly 
precipitated (Figure 4.3A). Parameters that may cause protein precipitation or 
B 
A 
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enhance protein solubility were investigated and factors that were found to 
have clear contribution to the protein purification are described below. 
 
 
4.1.3 Factors that have impact on protein purification 
 
Among factors that were examined (including buffer compositions and pH, 
purification temperatures, salt types and concentrations, reducing agents), 
three factors were found to have clear effects on protein solubility that are 
temperature, the presence or absence of reducing agents, and the salt 
concentrations in protein buffers.  
 
Temperature 
 
Initially, the protein was purified at room temperature (R.T.). Although no 
precipitation was observed at small-scale purification, the sample could not be 
measured by DLS at 20°C, most likely because of high  polydispersity that are 
out of range of DLS. When the measurements were performed at 4°C, however, 
it was possible to collect DLS data and the protein was relatively monodisperse 
(with polydispersity of 21.7%) (Figure 4.2). These results suggest that the 
protein was quickly aggregated at R.T and 4°C was necessary to keep the 
protein at monodisperse form. Thus, all steps of affinity protein purification were 
performed in cold room, all buffers were pre-chilled before using, the 
chromatography steps were performed using ÄKTA system in the fridge (at 
12°C) and the collected fractions were moved to and stored in cold room as 
soon as possible before the purification procedure ends.  
 
 
 
 
Figure 4.2: DLS analysis of purified PlaB. The first peak corresponds to the protein: At 4°C, 
the hydrodynamic radius of the protein is around 4 nm, with the percentage of polydispersity is 
21.7, suggesting the protein is monodisperse. The other peaks may be aggregates or dust. 
Measurement at 20°C could not be obtained with the notification from the measurement 
software that the sample was out of measurement  range of DLS. 
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Reducing agents 
 
Although low purification temperature keeps the protein monodisperse during 
small-scale purification (from 1-2 L cell culture), it could not prevent protein 
precipitation at high yield (Figure 4.3A). The protein sequence of PlaB contains 
5 cysteines. Information about disulfide bonding of the PlaB is currently 
unknown. The presence of cysteine gives high chance of non-specific cross-
linking of free cysteines between protein molecules, especially at high 
concentration, resulting in protein aggregation and precipitation. On the other 
hand, as PlaB is expressed in host cytoplasm, which is in reducing condition, it 
is also possible that a reducing environment is required for PlaB stability. 
Because initial purification protocol did not contain reducing agent, a high 
concentration of DTT was added directly into precipitated protein solution to 
verify if precipitation had been caused by cysteines. The precipitated protein 
was reversed into soluble form (Figure 4.3B).  
 
 
 
Figure 4.3: Effect of reducing agent on protein precipitate. A. Protein precipitated after 
large-scale purification. B: The protein precipitate was then treated by adding a small amount of 
1 M DTT stock. The solution became transparent, indicating the protein was reversed into 
soluble form. 
 
Salt concentration 
 
Another factor that may affect solubility of the protein is salt concentration (Van 
Pham et al., 2010). A buffer screen by gel filtration in different NaCl 
concentration was thus conducted simultaneously. The results revealed that 
the protein tends to aggregate at high concentration of salt (Figure 4.4). It is 
consistent with the suggestion from ThermoFluor assay conducted by Kuhle 
(personal communication). In fact, protein precipitation was observed some 
times when the protein was eluted with high concentration into buffer that 
contains high concentration of salt during cation exchange. As a result, the 
yield of protein was significantly reduced or almost all of protein was lost once it 
was precipitated. This step however, is unavoidable for protein elution in cation 
exchange chromatography. 
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Figure 4.4: SEC of 4 mg protein injected in buffers at different NaCl concentrations. The 
protein was injected into a S200 10/300 column in running buffer consisting of 20 mM HEPES 
pH 7.0, 5 mM DTT, and NaCl at concentrations indicated above. Sample volume: 0.5 ml; Flow 
rate: 0.3 ml/min. As seen in the gel filtration profile of PlaB at each salt concentration, the 
higher the salt concentration, the earlier the protein eluted, except the one at 20 mM NaCl, 
which was eluted at much later retention volume. The other peak appeared in the gel filtration 
profile at 50 mM NaCl with much lower peak maximum was not PlaB and intractable on SDS-
PAGE. They might be small molecules.   
 
 
4.1.4 Reverse anion exchange with optimized buffers  
 
A different protein purification scheme was therefore tested to overcome the 
effect of high salt concentration. Reverse anion exchange was applied after 
affinity purification. The PlaB protein was eluted during flow through of anion 
exchange and therefore was maintained in low salt (100 mM) buffer (Figure 
4.5). 10 mg protein with high purity and homogeneity were obtained from 3 L of 
cell culture (Figure 4.6B). The protein can be flash-frozen with liquid Nitrogen 
and stored at -80° for long-term usage. There was no degradation sign after 2 
weeks at 4°C and R.T. This final scheme is described in Figure 4.6C. 
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Figure 4.5: Reverse anion exchange purification of PlaB. A: Reverse anion exchange 
chromatogram of PlaB from a Mono Q column; blue: A280 of the protein; red: Conductivity. The 
protein did not bind to the column and could be collected in low-salt buffer (100 mM NaCl, low 
conductance), while impurities bound to the column and eluted later. B: SDS-PAGE analysis of 
the protein collected after affinity purification; lane M: protein marker, lanes 2-10: elution 
fractions. C: SDS-PAGE analysis of the protein collected after reverse anion exchange; lane M: 
protein marker, lanes 1-12: collected fractions. The collected fractions were intentionally loaded 
at high amount to access the protein purity. The impurities were not seen on Coomassie 
stained SDS-PAGE even at doubled protein amount loaded on the gel.  
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Figure 4.6: Comparison of protein yield purified from two above-described schemes. A: 
Protein purified from the first scheme. In this scheme scheme, the protein was purified through 
three steps: affinity purification, cation ion exchange and SEC. The protein was then pooled 
down and concentrated to 5 mg/ml. The final amount of protein is 2 mg from 3 L of cell culture. 
B: Protein purified from the optimized scheme. In this scheme, reverse anion exchange was 
following affinity purification as the final purification step. The final amount of protein after being 
concentrated is 10 mg from 3 L of cell culture. C: Final protein preparation scheme: The protein 
is expressed in Tuner cells at 200C overnight. The cell pellet was harvested and purified in two 
steps, Strep-tag affinity purification and reverse anion exchange. The protein is then 
concentrated to either 5 mg/ml or 10 mg/ml, aliquoted and flash frozen by liquid Nitrogen for 
long-term storage at -800C. There is no change in crystallization behavior of the protein before 
and after being frozen. 
 
 
4.1.5 Simplifying protein preparation procedure 
 
In the first year of the project, the protein was prepared by 2 persons at 2 
places. First the protein expression at small scale and affinity chromatography 
purification was carried out in Robert Koch Institute. The protein was then 
either picked up or brought over to the HZI for further steps of purification and 
crystallization. 
 
Affinity purification 
     Crystallization 
           Reverse anion exchange 
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As mentioned above, a large amount of purified protein in the same batch was 
required. Due to the lack of capacity for large-scale protein expression in 
Robert Koch Institute, large-scale protein expression was moved to the HZI. 
However, as wild type protein has hemolytic activity, it is not allowed to work 
with the protein in S1-lab and an S2-lab was not accessible at that time. Hence, 
the inactive PlaB mutant D203N was used. No change in physical behaviors of 
D203N mutant compared to the wild type was observed.  
 
 
4.2 Characterization of PlaB at different concentrations 
 
4.2.1 Size-exclusion chromatography (SEC) analysis 
 
For SEC analysis, the protein was injected into S200 10/300 column in buffer 
consisting of 20 mM HEPES pH 7.0, 100 mM NaCl, 5 mM DTT. A significant 
shift of the retention volume of the protein at low and high concentration (Table 
4.1, Figure 4.7) has been observed. While the retention volume of the protein at 
1 mg/ml was 13.54 ml, the eluted peak of the protein at 10 mg/ml was 12.51 ml, 
which raises the question whether PlaB changes its oligomerization state 
depending on the protein concentration.   
 
 
Table 4.1: Retention volumes of PlaB in SEC 
Protein Known MW 
(kDa) 
Concentration 
(mg/ml) 
Retention volume of peak 
maxium (ml) 
Conalbumin 75 1 14.2 
PlaB  1 13.54 
Aldolase 158 1 12.75 
PlaB  10 12.51 
The retention volumes were determined by integrating the A280 absorbance peak of SEC using  
UNICORN software.     
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Figure 4.7: SEC analysis of PlaB at low and high protein concentrations. A: SEC profiles 
of tested proteins. All proteins were injected into a S200 10/300 column in running buffer 
consisting of 20 mM HEPES pH 7.0, 100 mM NaCl and 5 mM DTT. Sample volume: 0.5 ml; 
Flow rate: 0.3 ml/min. The absorbance 280 nm was normalized to 1. B: SDS-PAGE analysis of 
PlaB collected from the SEC run; lane 1: protein marker, lane 2-3: fractions collected from 
highest gel-filtration peak of PlaB at the concentration of 1 mg/ml, lane 4-5: fractions collected 
from gel-filtration peak of PlaB at the concentration of 10 mg/ml.  
 
 
To estimate the oligomerization state of the PlaB at these two concentrations, 
Aldolase and Conalbumin were used as controls. A linear function (y = a + bx) 
showing correlation between logarithm of molecular weight and corresponding 
retention volume was established based on known molecular weights of 
Adolase and Conalbumin (Whitaker 1963). The molecular weight of PlaB 
monomer is 53 kDa. The results suggested that 13.54 ml corresponds to a 
molecular weight of 116.2 kDa, which is approximately a dimer, and 12.51 ml 
corresponds to a molecular weight of 195.79 kDa, which is approximately a 
A 
B 
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tetramer (Table 4.2). The results are consistent with results from small-angle X-
ray scattering, which suggested that PlaB is a tetramer and probably composed 
of a dimer of dimers (Kuhle, personal communication).  
 
 
Table 4.2: Calculation of MW of PlaB at low and high protein concentrations 
Protein Known 
MW (kDa) 
a b x (ml) y = a+ bx 
= log(MW) 
Calculated 
MW (kDa) 
Conalbumin 75.00 5.04 - 0.22 14.20 1.92  
Adolase 158.00 5.04 - 0.22 12.75 2.24  
PlaB (1 mg/ml)  5.04 - 0.22 13.54 2.07 116.20 
PlaB (10 mg/ml)  5.04 - 0.22 12.51 2.29 195.79 
 
 
4.2.2 Dynamic Light Scattering (DLS) analysis 
 
DLS is usually used to evaluate the aggregation state and to measure 
polydispersity of a protein (Proteau et al. 2010). Percentage of polydispersity is 
predictive of crystallisability (Borgstahl 2007). It is not suggested to use DLS to 
determine molecular weight of the protein, but it is possible to observe if there 
is any change in oligomerization state of the protein at different concentrations.  
 
For DLS experiment, the protein was measured at 4 different concentrations: 1 
mg/ml, 5 mg/ml, 7.5 mg/ml and 10 mg/ml. At three latter concentrations, there 
is no significant change in RH of the protein, suggesting that there is no change 
in oligomerization state at the protein concentration from 5 mg/ml to 10 mg/ml 
(Figure 4.8). At 5 mg/ml and 7.5 mg/ml, the protein was monodisperse, 
suggesting these concentrations are suitable for crystallization. It was not 
possible to obtain a qualified reading with a protein concentration of 1 mg/ml 
due to increased baseline and very high SOS error, suggesting that at low 
concentration, the protein is highly polydisperse. 
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Figure 4.8: DLS profile at different concentrations after purification. 25 measurements 
were carried out for each sample at 4°C. A. Protein concentration of 5 mg/ml (RH = 3.5 
nm; %PD = 21.7); B. Protein concentration of 7.5 mg/ml (RH = 3.1 nm; %PD = 15.9); C. Protein 
concentration of 10 mg/ml (RH = 3.6 nm; %PD = 35.6). The %PD equal to or smaller than 20% 
indicates the sample was monodisperse and RH of about 3 – 3.5 nm is in the range of non-
aggregated protein molecules. 
 
 
4.3 Crystallization 
 
4.3.1 Initial crystallization 
 
Based on the DLS results, purified protein was screened at the concentrations 
of 5 mg/ml against various commercial crystallization kits covering 960 different 
A 
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conditions. Right before crystallization, the protein solution was centrifuged at 
14,000 rpm at 4°C for 20 minutes to remove any possible precipitation. The 
crystallization screening was carried out at R.T in a sitting drop setup and the 
crystallization plates were incubated at 4°C and 20°C. Three crystal forms were 
obtained (Figure 4.9) in a broad range of screening conditions. PEG was the 
precipitant in most of these conditions. Crystals of suitable size were subjected 
to x-ray diffraction experiments but the diffraction resolution was not better than 
8 Å. Conditions that yielded best diffracted crystals (Figure 4.9A & B) were 
chosen for further optimization.  
 
 
 
 
 
4.3.2 Triclinic crystals 
 
Rod-shaped crystals appeared in several initial conditions but the condition in 
which crystals showed diffraction was 0.1 M MES pH 6.5, 10% PEG 6000. PEG 
concentration screen in the range of pH from 5.5 to 8.5 gave the optimized 
crystals in 0.1 M MES pH 5.5, 5% PEG 6000 at 20°C. The best crystal 
diffracted to a resolution of 2.6 Å at a micro-focus beamline ID-13 at ESRF 
 
Figure 4.9: Initial PlaB crystals. Crystals appeared after mixing 0.2 µl of the protein 
solution at 5 mg/ml with 0.2 µl of the according reservoir followed by incubation in a sitting 
drop setup at 20°C. A: hexagonal crystals obtained from 0.1 M MES pH 6.5, 15% PEG 400; 
B: rod-shaped crystals obtained from 0.1 MES pH 6.5, 10% PEG 6000; C: An example of 
needles appeared in various conditions. 
50 µm 50 µm 
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(Figure 4.10).  Additive screen was also tried in the attempt to obtain bigger 
and thicker crystals. However none of the additives improved the crystal quality. 
Several cryoprotectants were tested including glycerol, PEG 400, PEG 200, 
and paraffin. The crystals diffracted best and no ice ring was seen when using 
20% glycerol as the cryoprotectant. A solution of reservoir buffer including 20% 
glycerol was prepared, the crystal transferred from its drop into this solution 
and then quickly frozen in liquid nitrogen.  
 
 
 
4.3.3 Hexagonal crystals 
 
The initial crystallization condition of hexagonal crystals was 0.1 M MES pH 6.5, 
15% PEG 400. The crystal diffracted to a resolution of 5 Å at BESSY 
synchrotron. To improve the diffraction resolution, the condition was optimized 
by focusing on the precipitant and the pH. A screen of different PEGs with 
different molecular weights gave a crystal with improved diffracting resolution of 
2.5 Å.  
 
 
 
Figure 4.11: Optimized hexagonal crystals. Optimized crystals obtained after mixing 1 µl of 
the protein solution at 5 mg/ml with 1 µl of the according reservoir followed by incubation in a 
hanging drop setup at 20°C. The crystal was quickly deep into cryoprotectant solution and then 
frozen in liquid nitrogen. X-ray measurement of this crystal was carried out at beamline ID-29 at 
ESRF. 
 
Figure 4.10: Optimized triclinic crystals. Optimized crystal obtained after mixing 1 µl of the 
protein solution at 5 mg/ml with 1 µl of the according reservoir followed by incubation in a hanging 
drop setup at 20°C. The crystal was quickly dipped into cryoprotectant solution and then frozen in 
liquid nitrogen. X-ray measurement of this crystal was carried out at microfocus beamline ID-13 at 
ESRF.     
 
200 µm 
200 µm 
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4.3.4 Significant observations during protein crystallization 
 
Three observations made during the protein purification process contributed to 
the optimization of protein crystallization, and vice versa. Firstly, the protein 
behavior was irreproducible among different batches of protein purification 
(Figure 4.12). This further emphasized the need of preparing protein in large 
scale for higher reproducibility of crystallization (See section 4.1.2). 
 
Secondly, crystallization of the protein in the presence of DTT or TCEP as an 
additive suggested that DTT was better for protein crystallization. The crystals 
were able to form in the presence of DTT but not TCEP. 5 mM DTT, therefore, 
was then added into buffers at every steps of protein preparation. 
 
 
 
 
Figure 4.12: PlaB crystal’s behavior among batches. A-C: Crystals of three different 
batches of protein preparation at small scale (from 1-2 L cell culture). D: Large scale protein 
preparation in buffer without DTT resulted in aggregation (See section 4.1.3). E: Crystal 
obtained from a large scale protein preparation batch in buffer containing DTT.   
 
 
Thirdly, the crystals were obtained at 20°C. An SDS-PAGE analysis showed 
that there is no visible degradation of the protein in the crystals after two weeks 
(Figure 4.13). As mentioned in section 4.1.4, there was also no sign of protein 
degradation in solution. No degradation at this temperature gives good chance 
for the protein to be crystallized in full-length form.  
 
 
50 µm 50 µm 50 µm 
50 µm 
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Figure 4.13: SDS-PAGE analysis of PlaB crystals. From left to right: lane 1: protein marker; 
lane 2: PlaB crystals dissolved in sample buffer; lane 3: a different batch of purified PlaB 
 
 
4.4 Crystallographic analysis 
 
Datasets were collected at ESRF micro-focus beam line for rod-shaped crystals 
and at BESSY for hexagonal crystals. The rod-shaped crystal diffracted up to 
2.6 Å and belongs to P1 space group. The hexagonal one diffracted up to 2.7 Å 
and belongs to P6x22 space group. The datasets were processed with XDS 
(Kabsch 2010). The numbers of monomers per asymmetric unit were 
calculated using Mathews cell content analysis in CCP4 suite (Diseases 1968; 
Winn et al. 2011; Kantardjieff & Rupp 2003) (Table 4.3). 
 
Processing of datasets of hexagonal crystal using L-test in CCP4 suite (Padilla 
& Yeates 2003; Winn et al. 2011), however, revealed that the crystal is a 
perfect twin.  
 
 
Table 4.3: Data statistics of the optimized crystals 
 The hexagonal crystal The rod-shaped crystal 
Resolution (Å) 20.0 - 2.7 (2.8 - 2.7) 20 - 2.6 (2.7 – 2.6) 
Space group P6X22 P1 
Average unit cell 
dimensions (Å) 
197.9 / 197.9 / 175.2 102.1, 89.7, 104.5 
α /β/γ (°) 90.0 / 90.0 / 120.0 75.9, 90.1, 93.6 
Rmerge (%) 9.4 (75.4) 9.3 (43.4) 
Mean ((I)/σ(I)) 15.4 (2.4) 7.5 (1.8) 
Completeness (%) 98.4 (97.9) 92.7 (84.3) 
No. of monomers per au 4 8 
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Additive screen and crystallization at high temperature (30°C) were tested in 
the attempt to solve twinning problem. Expected untwinned dataset has L 
statistics of 0.5 while L statistic of a perfect twin is 0.375. Interestingly, the 
crystal obtained with the presence of potassium chloride as an additive has L 
statistic increasing to 0.438, near the value of an untwinned dataset. Some 
crystallization conditions producing rod-shaped crystals also contained 
potassium chloride as a salt, suggesting that potassium chloride may play a 
role in crystal packing, and further experiments with different concentrations of 
potassium chloride are worth to be tried.   
 
With a perfect twin, twinned intensities can increase 50% more and thus 
diminishes the inherently small anomalous signal (which only add 0.5% to 15% 
to the diffraction intensity). Experimental phasing has been rarely successful 
with twinned data (Rupp 2010). Molecular replacement solutions are in general 
less sensitive to twinning, and in these cases the problem usually becomes 
evident in the refinement stage. However current progress in computer 
program allows refinement against twinned data, made molecular replacement 
possible to use for phasing with twinned data. Therefore, molecular 
replacement was tested for the twinned dataset of PlaB.  
 
 
4.5 Molecular replacement 
 
Swiss-Model (Arnold et al. 2006), FUGUE (Shi et al. 2001), NCBI protein blast 
and Phyre (Kelley & Sternberg 2009) were used to search for structural 
homologs of PlaB. Among these programs, Phyre gave models of known 
structures with highest sequence identity and appropriate sequence alignment. 
Except the first template with unknown function, the others also belong to 
lipases (Figure 4.14). The highest sequence identity, however, is only 21% and 
all the templates only cover the N-terminal part of the protein. The highest 
coverage is only 37%. In order for molecular replacement to be successful, the 
sequence identity must be around 30% and the highest coverage of the search 
model must be at least 50% (Evans & McCoy). Sequence alignment between 
the model and PlaB suggests similarity in secondary structural contents at N-
terminal part of PlaB. However, it was only able to align the two residues Ser 
85 and Asp 203 with the respective ones in the search model. The third residue, 
His 251 is out of alignment area (Figure 4.15). Given all these information, no 
templates found were qualified as search model for molecular replacement. 
Attempts were then put on experimental phasing of triclinic crystals. The 
conventional heavy-atom derivatization method was first pursued. 
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Figure  
 
The lin 2722 protein with access code c3ds8a was used as a search model.  
The protein is from Listeria 2 with unknown function. This model covers 37% of 
the PlaB sequence. Sequence alignment between PlaB template and the 
model showed the well align of two first catalytic residues. The third one of 
PlaB was not aligned with the sequence of the model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Sequence and secondary structure alignment of search model (Lin2722) and 
PlaB.  Red arrows indicate catalytic residues. 
        
 
4.6 Heavy atom screening and co-crystallization 
 
HATODAS 2 server was used to predict which heavy atoms bind to the PlaB 
(Sugahara et al. 2009) . The result suggests that Sm, Hg, Au and Pt derivatives 
 
 
Figure 4.14: Potential structural homologs of PlaB detected by Phyre II (Kelley & Sternberg 
2009). The first column is the PDB id of the template. Alignment coverage indicates the area of 
sequence alignment between the models and PlaB. 
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were the most potential candidates. These derivatives were then screened by 
native gel to rule out the ones that do not bind to the protein or denature the 
protein (Boggon & Shapiro 2000). It is assumed that a heavy atom binding to 
the protein will lead to a shift on native gel because it provides additional 
charges to the protein. And if a protein is denatured by a heavy atom, it would 
precipitate and cannot move into the well of the native gel, resulting in the 
empty corresponding lane on native gel. An optimized protocol for native gel 
preparation and electrophoresis was established (Table 4.3). Figure 4.16 
shows that the protein was denatured in the presence of KAuBr, HgCl2, 
Hg(CH3COO)2 and K2PtCl6 and did not bind to Sm derivatives. The pattern in 
lane 6 and lane 7 are different from the one in lane 1. It is known that mercury 
binds to sulfur of sulfhydryl group of cysteine [Ref], and because there are 5 
cysteins in the protein sequence, it is highly possible that C3H6HgO2 and 
C2H7HgO4P might have bound to the protein. C3H6HgO2 and C2H7HgO4P were 
thus chosen for further experiments. I3C and I4C were also tested.  
 
 
 
 
Figure 4.16: Heavy atom screening. Lane 1: Native protein; Lane 2, 3, 10: Sm derivatives; 
Lane 4: KAuBr, Lane 5: Hg(CH3COO)2;Lane 6: C3H6HgO2; Lane 7: C2H7HgO4P; Lane 8: HgCl2; 
Lane 9: K2PtCl6. Lane 4, 5, 8, 9 were blank, an indication that the protein was severely 
denatured once mixing with respective heavy atoms, and precipitated, thus could not move into 
the wells. The pattern of lane 2, 3 and 10 are not different from lane 1, suggesting the Sm 
derivatives did not bind to the protein. Only mixtures running in lane 6 & 7 produced a relatively 
different pattern compared with the control in lane 1. Thus, C3H6HgO2 and C2H7HgO4P were 
chosen for preparing derivative crystals. 
 
 
To increase the opportunity for uniformity and completeness of heavy atom 
binding, and because the triclinic crystals were very fragile, they were co-
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crystallized with the protein at both conditions that gave hexagonal and triclinic 
crystals. No triclinic crystals were obtained. Co-crystallization of the protein with 
C3H6HgO2 resulted in crystals with bigger size than the native one of the same 
batch, but the size of each derivative crystal was still below 50 µm and the 
crystals had no diffraction (Figure 4.17). I3C and I4C did not give crystals with 
sufficient size for measurement (Figure 4.18). 
 
 
                                  Native crystals                     Hg-derivative crystals 
 
 
Figure 4.17:  Hg-derivative crystals 
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Figure 4.18: Different derivative crystals. A: I3C derivative; B: Co-crystallization of PlaB with 
I4C did not give crystals. C:  C3H6HgO2 derivative. 
 
 
The protein concentration that was used for crystallization was 5 mg/ml. One 
possible reason why C3H6HgO2 crystal has bigger size than the native one is 
that: in the presence of heavy atom, part of the protein was denatured, resulted 
in lower concentration of the protein and lower nucleation rate during 
crystallization process. To test this hypothesis, different concentrations of the 
protein were tested. However, there were no crystals produced at the protein 
concentration lower than 4 mg/ml. A protein concentration at 7.5 mg/ml and 10 
mg/ml resulted in quick aggregation or shower of needles.   
 
 
4.7 Establishment of an expression scheme for SeMet-
labeled protein 
 
Because heavy atoms did not give a promising result, SeMet was considered 
for production of derivative protein. There are two main stages in expression of 
SeMet-labeled protein. The first step was to grow the cells to high density 
(OD600 = 4). The cells were then harvested, washed and then divided into 4 
parts. In the second step, the cells were diluted into new media so that OD600 
was kept at 1. The cells were re-grown and induced in the presence of SeMet. 
 
50 µm 
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Four different expression schemes were tested (Table 4.4). In the first scheme, 
high density of cells were attempted to obtain by growing cells in minimal media 
plus methionine. The cells were then re-grown in minimal media in the 
presence of SeMet. In the second scheme, a mixture of amino acids (K, I, L, V) 
was added in the media at both steps. In the third scheme, minimal media was 
replaced by LB in the first step. No amino acids were added in both steps 
except SeMet was added in the second step. These three schemes of 
expression, however, resulted in cell death during growth or expression.  
 
 
Table 4.4: Schemes that were tested for expression of SeMet-labeled protein 
Scheme Conditions Result 
Stage 1 Stage 2 
1 Minimal media + Met Minimal media + SeMet Failed 
2 Minimal media + 
amino acid mix 
Minimal media + amino acid 
mix + SeMet 
Failed 
3 LB medium Minimal media + SeMet Failed 
4 LB medium Minimal media + amino acid 
mix + SeMet 
Successful 
 
 
To make the healthiest environment for cell growth, a protocol for expression of 
labeled-protein prepared for NMR was adapted. In the first step, LB was used 
to boost cell growth. In the second step when minimal media must be used to 
inhibit the synthesis of native methionine, the mixture of amino acids was 
added as supplements. With this protocol, it was able to keep the cell growing 
normal during induction. It was able to obtain 1 mg purified protein from 4 L of 
cell culture ready for crystallization (Figure 4.19). The incorporation rate of 
SeMet was nearly 90%. 
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Figure 4.19: SDS-PAGE analysis of purified SeMet protein. A: After affinity purification. 
From left to right: lane 1: marker, lane 2-7: elution fractions of affinity purification. B: After 
reverse anion exchange. From left to right: lane 1: marker, lane 2-9: fractions collected from 
reverse anion exchange. The band on SDS-PAGE was confirmed by Mass spec that it belongs 
to PlaB protein.  
 
 
4.8 Crystallization and crystallographic analysis of 
SeMet-labeled protein 
 
The best crystals after several rounds of optimization were obtained in the 
condition consisting of 0.1 M MES pH 6.5, 15% PEG 6000 or 0.1 M Tris pH 8.5, 
5% PEG 6000 and 50 mM KCl (Figure 4.20). The crystal could diffract up to 
2.29 Å under in-house beam line. The SeMet-labeled protein, however, was 
quickly aggregated just within 2 weeks even in -80°C storage. 
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Figure 4.20: SeMet optimized crystals. A: 0.1 M MES pH 6.5, 15% PEG 6000; B: 0.1 M Tris 
pH 8.5, 50 mM KCl, 5% PEG 6000; C: 0.1 M Tris pH 7.0; 3% PEG 6000, 0.1 M Potassium 
chloride; D: Tris pH 8.0, 3% PEG 6000, 0.1 M Potassium chloride; E: Tris pH 8.5, 3% PEG 
6000, 0.1 M Potassium chloride ; F: Tris pH 9.0, 3% PEG 6000, 0.1 M Potassium chloride; G: 
0.2 M MgCl2, 0.1 M HEPES pH 7.5, 15% (w/v) PEG 400. 
 
 
Se-absorbance scanning indicated that SeMet was incorporated into the crystal 
(Figure 4.21).  
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Figure 4.21: Se absorbance scan. F’ and f’’ are real and imaginary components of anomalous 
scattering factor, respectively. Typical anomalous scattering factors, f"max and f'min, estimated 
from X-ray spectra of protein crystals taken at MAD experimental stations, are 6 and -11, 
respectively (Wu et al. 1994). 
 
 
Data statistics of SeMet-labeled crystals indicated that the derivative crystals 
belong to the same space group with the native triclinic one, with almost the 
same unit dimensions (Table 4.5). However, an analysis of diffraction pattern of 
the crystal (Figure 4.22), together with Rmeas analysis versus frames (Figure 
4.23) revealed that the crystal has severe anisotropy, made it unable to be 
used for phase determination. 
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Table 4.5: Data statistics of SeMet crystals 
 Native SeMet derivative 
Resolution (Ǻ) 20-2.6 (2.7-2.6) 20 - 3.1 (3.2 – 3.1) 
Space group P1 P1 
Unit cell dimensions   
a, b, c (Ǻ) 75.9, 90.0, 93.6 75.9, 89.7, 93.3 
α, β, γ (°) 102.1, 89.7, 104.5 102.4, 90.0, 104.2 
Rmerge (%) 9.3 (43.4) 28.8 (80.0) 
Mean I/σ (I) 7.5 (1.8) 6.9 (2.7) 
Completeness (%) 92.7 (84.3) 98.6 (98.3) 
Redundancy 2.0 5.5 (5.5) 
SigAno > 1.1  20 Ǻ - 3.9 Ǻ 
 
 
 
Figure 4.22: X-ray diffraction pattern reveals anisotropy. Red arrows show smeared 
reflections as an indication of anisotropy.  
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Figure 4.23: Rmeas analysis (Rupp 2010). It should be noticed that the native and derivative 
data sets were collected at two different beamlines. The native dataset was collected at micro-
focus beam, while the derivative one was collected at normal beam-line. 
 
 
4.9 Tackling anisotropy by changing external 
parameters 
 
To solve anisotropy issue, external parameters were varied. Temperature, 
seeding, precipitation screen and pH screen were tried. Additive screens and 
silver bullet have been also tried in the attempt to obtain better diffraction 
quality crystals or crystals of different morphology. No significant improvement 
was obtained.   
 
 
4.10 Co-crystallization of the protein with its substrates 
 
Obtaining structure of PlaB in the complex with its substrate is one of the goals 
of this research project. Besides, ligand binding might stabilize the protein 
(Dekker, 1999) and results in better crystal packing, which may overcome 
twinning or anisotropy issues. Thus co-crystallization of PlaB D203N with its 
substrates was carried out. Point mutation D203N results in an inactive enzyme 
but may not alter the structure of the protein, due to similarity in structures of D 
and N. Therefore it can be assumed that the enzyme will not cleave the 
substrate, leaving the substrate intact in the binding pocket. It has not been 
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confirmed if the substrate really remains in the enzyme.  
 
For co-crystallization of PlaB with its substrates, the substrates (PC, LPC, PG) 
were dissolved in either in Triton X-100, or 1.1% Octyl-β-D-glucopyranoside 
(OG), or 5% DMSO. Triton X-100 was used to dissolve the lipids for functional 
assay of PlaB (Kuhle, personal communication). OG is a nonionic detergent 
that is very common in crystallization of membrane protein and liposome 
reconstitution (Newby et al. 2009; Raman et al. 2006; Ferrandon & Newstead 
2008). DMSO is a common solvent for dissolving organic molecules. The 
substrates were soluble in Triton X-100 and DMSO. 1.1% OG could not 
dissolve PC and PG completely. However, the best crystal hits were obtained 
when the substrates were dissolved in OG, although the size of the crystals 
was not sufficient for X-ray measurements and no new crystal morphology was 
found (Figure 4.24).   
 
 
 
Figure 4.24: Initial hits of PlaB co-crystallized with its substrates dissolved in 1.1% OG. 
No crystals of PlaB in complex with PG. Crystallization conditions: For A, B, C: 0.1 M MES pH 
6.5 and 15% (w/v) PEG 400; D, E, F: 0.2 M Ammonium sulfate, 0.1 M Bis-Tris pH 5.5 and 25% 
(w/v) PEG 3350. G, H, I: 0.2 M Ammonium acetate, 0.1 M Bis-Tris pH 5.5 and 25% PEG 3350. 
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4.11 Crystallization of chemically-modified protein 
 
4.11.1 Lysine methylation 
 
Various attempts focusing on external parameters to remove twinning and 
anisotropy issues have not resulted in positive outcomes. Chemical 
modifications of proteins were thus considered. The first, most simple approach 
is lysine methylation. Lysines are generally exposed on the surfaces of proteins 
and can disrupt well-ordered crystal lattice owing to its flexible amino acid side 
chains. Chemical modification of surface lysine residue help reduce surface 
entropy and thus may improve crystal packing, resulting in better diffracting 
crystals (Kobayashi et al. 1999; Kurinov et al. 2000; Rayment et al. 1993; 
Rayment 1997). The most common approach is the reductive methylation of 
free amino groups in which primary amines (i.e., lysine residues and the N 
terminus) are modified to tertiary amines.  
 
The reaction was carried out according to the protocol (Walter et al. 2006). The 
methylated product was then purified by SEC (Figure 4.25A). 25% of protein 
amount remained soluble after lysine methylation (Figure 4.25B). The protein 
was concentrated down and initial crystallization screen was performed. 
However, crystallization of lysine-methylated protein only resulted in shower of 
needles (Figure 4.26). A grid screen of pH/PEG concentration did not improve 
the results.  
 
 
 
Figure 4.25: Purification of methylated lysine protein. A: Chromatogram of SEC run. 
Absorbance at 280nm is shown in blue. The arrows indicate the area that the elution fractions 
were collected. B. SDS-PAGE analysis of fractions collected from SEC purification of the 
protein after lysine methylation. Yield of the protein after lysine methylation reduced from 6 mg 
to 1.44 mg (25% remained after lysine methylation) 
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Figure 4.26: Lysine-methylated crystals. Crystallization conditions: A: 0.1 M MES pH 6.5, 
15% (w/v) PEG 400; B: 2.4 M Sodium malonate pH 7.0. 
 
 
4.11.2 Expression, purification and crystallization of C-terminal 
truncated protein 
 
As mentioned above, the aim of the thesis is to determine the structure of a 
biological active enzyme (Although the working full length protein is the inactive 
mutant, it is assumed that there would be no significant difference in structure 
between wild type and D203N owing to similar structure of the two amino acids 
D and N). Truncation of only 15 amino acids at the C terminus of PlaB is 
sufficient to abolish the enzyme activity. Structure of a truncated enzyme thus 
may not give the answer on the enzyme’s activity mechanism.  
 
However, consensus secondary structure prediction at NPS@ (Deléage et al. 
1997) suggests that the last 15 amino acids may be random coil (Figure 4.27). 
Removing this part may reduce flexibility of the protein which improves crystal 
packing. If a structure of a truncated version of PlaB in which the last 15 amino 
acids are deleted can be obtained, it can serve as a search model for molecular 
replacement to solve the structure of the full-length protein.  
 
 
 
 
50 µm 50 µm 
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Figure 4.27: Consensus secondary structure prediction of PlaB’s C-terminus. 
UNK_184590 is a designated id of PlaB sequence. DPM, DSC, HNNC, NLRC, PHD, Predator, 
SOPM are programs for secondary structure prediction. Sec.Cons. stands for secondary 
structure consensus. 
  
 
Thus a truncated version of PlaB in which the last 15 amino acids were deleted 
(hereby designated as D203N_459) was expressed and purified following the 
protocol for full length protein (Figure 4.28). The protein was monodisperse on 
gel filtration with calculated molecular weight of 181.6 kDa derived from 
function given in Table 4.2. This allows estimation that the truncated protein is 
tetramer.  
 
 
  
Figure 4.28: Analysis of C-terminal truncated PlaB after purification. A: SDS-PAGE 
analysis. E20 and E30 are the elution fractions after affinity purification. The number 20 and 30 
mean the protein was expressed at 20°C and 30°C, respectively. Although the protein yield 
was higher when being produced 30°C, the protein is prone to aggregation. RAEX fractions are 
the protein fractions collected during reverse anion exchange chromatography. B: SEC analysis 
of RAEX fractions. 
 
 
Purified protein was screened against various commercial crystallization kits. 
Crystals with different morphology were obtained (Figure 4.29), giving hope 
that the crystals may not have twinning or anisotropy problems. However the 
A B 
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crystals were still too small for x-ray measurements. Further optimization is 
needed to improve the size of the crystals. 
 
 
 
 
Figure 4.29: Initial crystals of D203N_459. The crystallization condition was 0.1 M HEPES 
pH 7.5, 20% PEG 6000. The full length protein also crystallized in either HEPES pH 7.5 or PEG 
6000 and formed triclinal crystals. However, the crystal of D203N_459 has different morphology 
compared with full length protein. 
 
 
4.11.3 Proteolysis screening  
 
Limited proteolysis was used to identify globular and stable protein domains 
(Wernimont & Edwards 2009). The full length and C-terminus truncated 
proteins were treated with the proteases in Hampton kit as described in section 
3.2.3.4. The products were analyzed by SDS-PAGE.  
 
As shown in Figure 4.30, there is only a small portion of the protein was 
susceptible to different proteases, indicating by a smear pattern containing 
multi bands of lower MW with much weak intensity comparing with the full 
length band. The construct D203N_459 seems to be more stable. There was 
almost no degradation after 4 hours incubated with EG-C, EL, PA and PE 
(Figure 4.30B), while a small portion of the full length one was cleaved (Figure 
4.30A). No stable sub-domain of PlaB was obtained for isolation and 
crystallization from these experiments. 
 
50 µm 
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Figure 4.30: Proteolysis screening of full length (A & C) and C-terminus truncated 
proteins (B & D). The protein was incubated with enzymes for: (A) & (B): 4 hours; (C) & (D): 
overnight. FL: full length protein; tru: D203N_459. 
 
 
4.11.4 Surface entropy reduction (SER) mutants  
 
To identify SER mutants for construction, two approaches were tried. The first 
approach that was carried out by Kuhle relied on SERp Server (Goldschmidt et 
al. 2007). The second approach was to design all mutations around regions 
that are rich of hydrophilic amino acids (Cooper et al. 2007; Longenecker et al. 
2001).   
 
SER mutants suggested by SERp Server 
 
These two surface mutants were constructed by K. Kuhle. In the first mutant, 
cluster EHKE (306 - 309) were changed to SHSS. In the second mutant, cluster 
KQGK (29 – 32) was mutated to SSGS. The proteins were expressed and 
purified according to the protocol for wild type PlaB. These two mutants, 
unfortunately, were heavily aggregated after affinity purification (Figure 4.31). 
The final concentration of the protein was 0.7 mg/ml which is usually insufficient 
for protein crystallization. An initial crystallization screen was still carried out but 
did not produce any crystals.  
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Figure 4.31:  Absorbance scan of elution fractions of two surface mutants purified from 
Strep-tag affinity column. There were no peaks seen at A 280 nm in all elution fractions, 
suggesting that the proteins were precipitated.  
 
 
Proposal for rational mutagenesis of predicted surface residues 
 
Hydrophilic residues that usually reside on the surface of a protein were chosen 
for mutagenesis (Figure 4.32).  20 mutants were decided (Table 4.6) and 
primers for these 20 mutants were synthesized. Generation of these mutants is 
under way. 
 
 
Figure 4.32: Sequence of full length PlaB. Bold letters are residues predicted to be on the 
surface of the protein. 
 
MIVIFVHGWSVTHTNTYGELPQWLENQSKQGKLDIQVGNIYLGRYISFDDT
VTVDDIARAFDQAVRDEIADKLRDGQRFACITHSTGGPIVRKWMDLYFKSN
LAKCPLSHLIMLAPANHGSALAQLGKSRLGRIKSFFEGIEPGKCVLDWLELG
SDMSWQLNESWLDYDCTANGVYSFVLTGQKIDRQFYDAVNSYTGESGSD
GVVRVAATNMNYSLLKLHQEGDNGESLVVAKMTRTQPMAFGVLPGLSHS
GKNIGIIRSITMANAATHPTAIWILRCLQVKSRDSYNKLVKELDNITKETQKN
EHKEFVKTLVFTREYITNRYSMIIFRLIDDRGNHLIDYDLYLTAGPQYSEQAL
PAGFFVDRQRNLNNRGKLTYFLDYDIMEGGINTPKMQGNLGFRVKAYPES
SDQALAYYRLLDFHSSLADIHKILHPNETVMVEIMLQRRVDRTVFRISNNLT
PAKISGKPTGKKID 
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Table 4.6: Proposed SER mutants 
K29AQ30AK32A K29SQ30SK32S 
E142AK144A E142SK144S 
K292AE293A K292SE293S 
K299AE300A K299SE300S 
E300AQ302AK303A E300SQ302SK303S 
K303AE305A K303SE305S 
K307AE308A K307SE308S 
E355AQ356A E355SQ356S 
R401AK403A R401SK403S 
K471AK472A K471SK472S 
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5 Discussion 
 
PlaB is a member of a novel lipase family (Bender et al. 2009) and is the most 
prominent cell-associated phospholipase A of L.pneumophila (Schunder et al. 
2010). It exhibits both PLA and LPLA activity, and has hemolysis potential, 
through which it exposes its virulence. The enzyme also possesses unique 
features in the amino acid environment of catalytic residues which are not 
found in any characterised lipases. Because no homolog structure is available, 
structural determination of PlaB would set a foundation to visualize the activity 
of the protein and furthermore, to understand an important step in pathogenesis 
of L. pneumophila.  
 
For this purpose, X-ray crystallography was chosen. Because truncation of only 
15 amino acids at the C-terminus abolishes enzyme activity, attempts were 
spent on full-length protein to get structure of a biologically active protein. A 
preparation scheme for full length PlaB was established, the protein was 
characterised, native data set of full length protein was obtained, and various 
attempts were spent to obtain a derivative crystal that is qualified for phase 
solution step.  
 
 
5.1 Purification and characterization of PlaB  
 
 The purification and characterization of the protein is the first and also the 
single most important step in working flow for crystallization (McPherson 1999).  
 
Structure of a crystal is formed by naturally chemical bonding between 
molecules. Crystallization thus requires that the sample must be pure and 
homogeneous to ensure no interference by impurities or unnatural forms of the 
protein molecules (eg. aggregation). A study showed that proteins of unknown 
structure with purity level of > 95% judged by SDS-PAGE were successfully 
crystallized in 59% of all cases, whereas samples that were < 95% pure yield 
crystals with a success rate of only 37% (Geerlof et al. 2006). However, there is 
still no certain rule of how pure is pure enough. In the case of eubacterial 
aspartyl-tRNA synthetase, a purity level of ~99% is required for the production 
of high-quality crystals (Moreno et al. 2005). An amount of less than 5% of 
AcrB, which was not detectable on SDS-PAGE, as a contaminant in 
preparation of another target protein was sufficient for the protein to crystallize, 
while the target protein failed to crystallize (Veesler et al. 2008). 
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A preparation scheme for PlaB was established yielding sufficient amounts of 
protein qualified for crystallization. Factors that can affect the solubility of the 
protein were investigated.  It is not uncommon for one batch of protein 
crystallizes while the next will not, and for many cases, the factor(s) that 
decides this difference can only be identified once the protein structure is 
solved (Mc Ree 1999), or takes a remarkable time to find out. It happened in 
the case of PlaB, which showed different behaviors among protein batches. 
The most effective preparation scheme not only must ensure a reasonably high 
amount of sample for crystallization at one time, but also should be as simple 
as possible. 
 
 
5.2 PlaB is not degraded but tends to aggregate at 
higher temperature 
 
SDS-PAGE analysis revealed that the full length PlaB was not degraded at R.T 
even after two weeks, either in solution or in crystal. However, DLS 
measurement was impossible for samples at R.T because the protein formed 
aggregation that is out of range for DLS measurement. DLS measurement 
could only be obtained when sample was at 4°C. Crystallization at 4°C resulted 
in no crystals but high numbers of clear drops, suggesting the protein was 
unable to aggregate in the time frame that was sufficient for protein crystallized 
at 20°C.  
 
There has been no biological relevance with this trend found in previous 
studies on phospholipases. The tendency for aggregation of PlaB may not be a 
physiological process but purely due to in vitro experimental conditions. High 
temperature increases the energy of motion of the protein chain, which may 
break relatively weak H-bonds, as well as electrostatic and hydrophobic 
interactions (Lebendiker & Danieli 2014), resulting in the collapse of the protein 
conformation and thus protein became aggregated.  
 
 
5.3 Oligomerization of PlaB in biological context 
 
Gel filtration of PlaB at high concentration suggested that in in vitro solution, the 
protein formed a stable tetramer. This observation is supported by analytical 
ultra-centrifuge analysis (Kuhle, personal communication). At lower 
concentration, the protein dissociated to dimer, suggesting that oligomerization 
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of PlaB is concentration-dependent. 
 
In nature, there are various examples in which the oligomerization interplay of a 
phospholipase controls its activity. For example, Staphylococcus aureus 
phosphatidylinositol-specific phospholipase C is inactive at monomer form, 
whereas dimerization leads to its activation. In the inactive state, soluble anions 
or anionic lipids bind to anion binding pockets of the enzyme and inhibits 
enzyme dimerization. PC activates the enzyme by binding to the lipase, 
therefore diluting anion substrate and allowing transient dimers to form (Cheng 
et al. 2012). E.coli outer membrane phospholipase A (OMPLA) present as an 
inactive monomer in the outer membrane of the bacteria. Phospholipid 
substrates activate the enzyme activity by inducing dimerization of the enzyme, 
resulting in the complete formation of substrate binding pockets and functional 
oxyanion holes (Stanley et al. 2007; Stanley et al. 2006). Usually, 
oligomerization is the activation mechanism of phospholipases. 
 
However, PlaB does not follow the above mechanism. Although the tetramer 
form of the protein is stable and monodisperse in gel-filtration, indicating that 
this is not a non-specific interaction, the protein is most active in monomer form 
indicated by in-vitro assay (Kuhle et al. 2014).     
 
PlaB does not participate in the internalization of Legionella pneumophila but 
rather at the bacterial replication and dissemination steps. So there must be a 
mechanism that regulates its activity and keeps the enzyme inactive at certain 
point in bacterial life cycle. It may be hypothesized that the tetramer form is the 
storage state of the enzyme. The binding of the substrates may lead to 
conformational change of the oligomer. The tetramer disassociate to monomer, 
resulting in the exposure of the active site. Further experiments are needed to 
confirm this hypothesis. 
 
Independently, by using biophysical and enzymatic essays, Kuhle et al. had 
also come to similar suggestion that oligomer may inhibits PlaB’s activity (Kuhle 
et al. 2014). 
 
As indicated in section 4.11.2, the protein was estimated to be tetramer after 
the truncation of the last 15 amino acids at C-terminus. This suggests that the 
last 15 amino acids, although play an on/off role in enzyme activity, do not 
contribute to the oligomerization of the enzyme.   
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5.4 Issues in crystallization 
 
Obtaining high quality crystals is a critical step for but has always been a bottle 
neck to protein structure determination by X-ray crystallography. To obtain 
good structural data, crystals need to be single and isotropic. Although it was 
able to obtain the PlaB protein at high yield and high homogeneity after several 
optimizations, which is supposed to be suitable for crystallization, crystals were 
obtained with reasonable resolutions, the crystals has always been perfectly 
twinned in hexagonal form or anisotropic in triclinic form. There is no clear rule 
on which condition gives hexagonal crystals, or which condition gives triclinic 
crystals. Both low MW and high MW PEG can give either hexagonal or triclinic 
crystals. Although hexagonal crystals did not appeared at pH above 8, rod-
shaped crystals appeared in a wide range of pH from 6.5 to above 8. It was 
even observed sometimes that a mix of hexagonal and rod-shaped crystals 
appeared in the same condition that had given hexagonal ones before. This 
behavior creates difficulties for optimization focus. For example, one may want 
to focus on solving twinning issue of the hexagonal crystals, but when 
repeating the crystallization condition and expanding optimization around the 
condition, the crystals turned out to be triclinic one.  
 
Other issues in crystallization of PlaB include quick aggregation that made 
crystal form just after 5 minutes, irreproducibility of crystallization behaviors 
between different batches of purified proteins, or even between different plates, 
pipetting of the same protein batch and crystallization condition.
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6 Outlook 
 
Vapor diffusion techniques were employed in this work to grow the protein 
crystals. In these techniques, evaporating the solvent from a droplet containing 
the purified protein buffered at a given pH and precipitant is the key to reach 
the supersaturation state needed for crystallization to occur. The evaporation of 
the solvent from the droplet occurs during equilibration of the droplet with a 
larger reservoir containing a solution at a higher precipitant concentration. The 
equilibrium state is attained when the vapor pressure at the droplet surface 
balances with the vapor pressure of the reservoir. At this point of time, the 
supersaturation is no longer affected by the solvent evaporation.  
 
Obtaining well diffracting crystals is in a great deal determined by solvent 
evaporation and thus by parameters governing the evaporation process. These 
parameters include the temperature, drop size and shape, and concentrations 
of crystallizing agent in the droplet and dehydrating agent in the reservoir 
(Boistelle & Astier, 1988; Fowlis et al., 1988; Mikol et al., 1990; Sibille et al., 
1991). 
 
Different approaches were tested in the attempt to control the rate of solvent 
evaporation. These include testing different concentrations and different types 
of PEGs, different pH, different crystallization temperatures, additive screen 
and silver bullets. These approaches did not produce a significant improvement. 
 
Among parameters that affect solvent evaporation, drop shape was not taken 
into account, and this maybe an important cause of protein crystallization 
behavior. This parameter, however, is the most difficult factor to reproduce. It 
heavily depends on manual handling, the material of the plates and the 
composition of the crystallization contents. While the material of the plates and 
composition of the crystallization contents can be keep constant during 
crystallization experiments, it is a challenge to make manual handling 
reproducible. 
 
Among chemical-modification approaches that have been tried to intervene the 
chemical nature of the protein and eventually to change crystal packing, a 
different crystal morphology was obtained by crystallizing a truncated version of 
PlaB where the last 15 amino acids, predicted to be disordered, were cut off. A 
different morphology gives hope that the crystal may not have twinning or 
anisotropy issue. This condition should be optimized further to obtain a crystal 
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with diffracting quality. If a structure of this version can be solved, it can be 
used as search model for determining structure of full-length protein whose 
native data set is available.  
 
Future work should focus on optimizing the crystals of the C-terminal truncated 
PlaB and crystallization of SER mutants to overcome twinning and anisotropy 
issues. It would then be hopeful that PlaB structure could be solved and 
establish a knowledge foundation for new drug discovery and to fully 
understand molecular mechanism of PlaB’s activities.  
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